{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:06:44Z","timestamp":1767625604868,"version":"3.40.3"},"publisher-location":"Cham","reference-count":613,"publisher":"Springer Nature Switzerland","isbn-type":[{"type":"print","value":"9783031612374"},{"type":"electronic","value":"9783031612381"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-61238-1_15","type":"book-chapter","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T06:03:06Z","timestamp":1724997786000},"page":"305-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gastrointestinal Malignancy: Genetic Implications to Clinical Applications"],"prefix":"10.1007","author":[{"given":"Hannah E.","family":"Trembath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen Jen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole E.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"key":"15_CR1","first-page":"344","volume":"102","author":"RM McAllister","year":"1965","unstructured":"McAllister RM (1965) Viruses and cancer. Calif Med 102:344\u2013352","journal-title":"Calif Med"},{"issue":"3","key":"15_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/carcin\/21.3.405","volume":"21","author":"JS Butel","year":"2000","unstructured":"Butel JS (2000) Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 21(3):405\u2013426","journal-title":"Carcinogenesis"},{"issue":"4607","key":"15_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.6336310","volume":"221","author":"JJ Yunis","year":"1983","unstructured":"Yunis JJ (1983) The chromosomal basis of human neoplasia. Science 221(4607):227\u2013236","journal-title":"Science"},{"issue":"6835","key":"15_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/35077207","volume":"411","author":"BA Ponder","year":"2001","unstructured":"Ponder BA (2001) Cancer genetics. Nature 411(6835):336\u2013341","journal-title":"Nature"},{"issue":"5547","key":"15_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/260170a0","volume":"260","author":"D Stehelin","year":"1976","unstructured":"Stehelin D, Varmus HE, Bishop JM, Vogt PK (1976) DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260(5547):170\u2013173","journal-title":"Nature"},{"issue":"6502","key":"15_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/372143a0","volume":"372","author":"TH Rabbitts","year":"1994","unstructured":"Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372(6502):143\u2013149","journal-title":"Nature"},{"issue":"4587","key":"15_CR7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.6336308","volume":"219","author":"WF Benedict","year":"1983","unstructured":"Benedict WF, Murphree AL, Banerjee A, Spina CA, Sparkes MC, Sparkes RS (1983) Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science 219(4587):973\u2013975","journal-title":"Science"},{"issue":"5925","key":"15_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/304451a0","volume":"304","author":"R Godbout","year":"1983","unstructured":"Godbout R, Dryja TP, Squire J, Gallie BL, Phillips RA (1983) Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature 304(5925):451\u2013453","journal-title":"Nature"},{"key":"15_CR9","doi-asserted-by":"crossref","unstructured":"Sparkes RS, Murphree AL, Lingua RW, Sparkes MC, Field LL, Funderburk SJ et al (1983) Gene for hereditary retinoblastoma assigned to human chromosome 13 by linkage to esterase D. Science. 219(4587):971\u2013973","DOI":"10.1126\/science.6823558"},{"issue":"4","key":"15_CR10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr","year":"1971","unstructured":"Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820\u2013823","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5035","key":"15_CR11","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1126\/science.1659741","volume":"254","author":"RA Weinberg","year":"1991","unstructured":"Weinberg RA (1991) Tumor suppressor genes. Science 254(5035):1138\u20131146","journal-title":"Science"},{"issue":"6707","key":"15_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/24179","volume":"396","author":"ML Fero","year":"1998","unstructured":"Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396(6707):177\u2013180","journal-title":"Nature"},{"issue":"6","key":"15_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrg816","volume":"3","author":"PA Jones","year":"2002","unstructured":"Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415\u2013428","journal-title":"Nat Rev Genet"},{"issue":"2","key":"15_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrc1799","volume":"6","author":"SB Baylin","year":"2006","unstructured":"Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6(2):107\u2013116","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"15_CR15","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042\u20132054","journal-title":"N Engl J Med"},{"issue":"2","key":"15_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJM200007133430210","volume":"343","author":"RN Hoover","year":"2000","unstructured":"Hoover RN (2000) Cancer\u2013nature, nurture, or both. N Engl J Med 343(2):135\u2013136","journal-title":"N Engl J Med"},{"issue":"6776","key":"15_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/35006081","volume":"404","author":"EM El-Omar","year":"2000","unstructured":"El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA et al (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404(6776):398\u2013402","journal-title":"Nature"},{"issue":"5730","key":"15_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/bmj.4.5730.259","volume":"4","author":"RB Scott","year":"1970","unstructured":"Scott RB (1970) Cancer chemotherapy\u2013the first twenty-five years. Br Med J 4(5730):259\u2013265","journal-title":"Br Med J"},{"issue":"2723","key":"15_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1126\/science.105.2723.243","volume":"105","author":"C Auerbach","year":"1947","unstructured":"Auerbach C, Robson JM, Carr JG (1947) The chemical production of mutations. Science 105(2723):243\u2013247","journal-title":"Science"},{"issue":"2","key":"15_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0022-2836(66)80004-9","volume":"19","author":"KW Kohn","year":"1966","unstructured":"Kohn KW, Spears CL, Doty P (1966) Inter-strand crosslinking of DNA by nitrogen mustard. J Mol Biol 19(2):266\u2013288","journal-title":"J Mol Biol"},{"key":"15_CR21","unstructured":"Board CNE (2023) Gastrointestinal stromal tumor\u2014GIST: Statistics 2023. https:\/\/www.cancer.net\/cancer-types\/gastrointestinal-stromal-tumor-gist\/statistics#:~:text=GISTs%20are%20rare%2C%20making%20up,develop%20in%20the%20small%20intestine"},{"issue":"1","key":"15_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1055-9965.EPI-14-1002","volume":"24","author":"GL Ma","year":"2015","unstructured":"Ma GL, Murphy JD, Martinez ME, Sicklick JK (2015) Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomark Prev 24(1):298\u2013302","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5350","key":"15_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577\u2013580","journal-title":"Science"},{"issue":"4","key":"15_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00000478-199904000-00002","volume":"23","author":"K Sircar","year":"1999","unstructured":"Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH (1999) Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 23(4):377\u2013389","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"15_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1572-0241.2005.40709.x","volume":"100","author":"T Tran","year":"2005","unstructured":"Tran T, Davila JA, El-Serag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 100(1):162\u2013168","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"15_CR26","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","volume":"130","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130(10):1466\u20131478","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"15_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1053\/j.sempedsurg.2016.09.004","volume":"25","author":"D Mullassery","year":"2016","unstructured":"Mullassery D, Weldon CB (2016) Pediatric\/\u201cWildtype\u201d gastrointestinal stromal tumors. Semin Pediatr Surg 25(5):305\u2013310","journal-title":"Semin Pediatr Surg"},{"issue":"1","key":"15_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-020-01026-6","volume":"14","author":"CM Kelly","year":"2021","unstructured":"Kelly CM, Gutierrez Sainz L, Chi P (2021) The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol 14(1):2","journal-title":"J Hematol Oncol"},{"issue":"8","key":"15_CR29","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/bjs.10809","volume":"105","author":"WTA van der Graaf","year":"2018","unstructured":"van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW (2018) Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. Br J Surg 105(8):1020\u20131027","journal-title":"Br J Surg"},{"issue":"5","key":"15_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1053\/hupa.2002.124122","volume":"33","author":"RP Dematteo","year":"2002","unstructured":"Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33(5):466\u2013477","journal-title":"Hum Pathol"},{"issue":"9440","key":"15_CR31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127\u20131134","journal-title":"Lancet"},{"issue":"4","key":"15_CR32","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol Off J Am Soc Clin Oncol 26(4):626\u2013632","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"15_CR33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D","volume":"92","author":"A Beghini","year":"2001","unstructured":"Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C et al (2001) Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 92(3):657\u2013662","journal-title":"Cancer"},{"issue":"4","key":"15_CR34","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-03-0110","volume":"10","author":"ME Robson","year":"2004","unstructured":"Robson ME, Glogowski E, Sommer G, Antonescu CR, Nafa K, Maki RG et al (2004) Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 10(4):1250\u20131254","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15_CR35","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/gast.2001.20880","volume":"120","author":"H Maeyama","year":"2001","unstructured":"Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A et al (2001) Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120(1):210\u2013215","journal-title":"Gastroenterology"},{"issue":"1","key":"15_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/01.pas.0000176433.81079.bd","volume":"30","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Fetsch JF, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30(1):90\u201396","journal-title":"Am J Surg Pathol"},{"issue":"14","key":"15_CR37","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-08-0086","volume":"14","author":"C Mussi","year":"2008","unstructured":"Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P (2008) Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 14(14):4550\u20134555","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/PAS.0b013e3181c20f4f","volume":"34","author":"L Zhang","year":"2010","unstructured":"Zhang L, Smyrk TC, Young WF Jr, Stratakis CA, Carney JA (2010) Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol 34(1):53\u201364","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"15_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.ejhg.5201904","volume":"16","author":"B Pasini","year":"2008","unstructured":"Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M et al (2008) Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 16(1):79\u201388","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"15_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/modpathol.2010.185","volume":"24","author":"J Gaal","year":"2011","unstructured":"Gaal J, Stratakis CA, Carney JA, Ball ER, Korpershoek E, Lodish MB et al (2011) SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol 24(1):147\u2013151","journal-title":"Mod Pathol"},{"issue":"2","key":"15_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1365-2559.2010.03624.x","volume":"57","author":"M Novelli","year":"2010","unstructured":"Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L et al (2010) DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 57(2):259\u2013270","journal-title":"Histopathology"},{"key":"15_CR42","doi-asserted-by":"crossref","unstructured":"Group ESESNW (2014) Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii21\u2013iii26","DOI":"10.1093\/annonc\/mdu255"},{"issue":"17","key":"15_CR43","first-page":"4297","volume":"59","author":"M Taniguchi","year":"1999","unstructured":"Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T et al (1999) Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59(17):4297\u20134300","journal-title":"Cancer Res"},{"issue":"22","key":"15_CR44","first-page":"8118","volume":"61","author":"BP Rubin","year":"2001","unstructured":"Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61(22):8118\u20138121","journal-title":"Cancer Res"},{"issue":"23","key":"15_CR45","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol Off J Am Soc Clin Oncol. 21(23):4342\u20134349","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"9","key":"15_CR46","first-page":"3329","volume":"9","author":"CR Antonescu","year":"2003","unstructured":"Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM et al (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9(9):3329\u20133337","journal-title":"Clin Cancer Res"},{"issue":"7","key":"15_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1542-3565(04)00243-5","volume":"2","author":"JF Emile","year":"2004","unstructured":"Emile JF, Theou N, Tabone S, Cortez A, Terrier P, Chaumette MT et al (2004) Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2(7):597\u2013605","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"15_CR48","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1053\/j.gastro.2006.01.043","volume":"130","author":"J Andersson","year":"2006","unstructured":"Andersson J, Bumming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H et al (2006) Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130(6):1573\u20131581","journal-title":"Gastroenterology"},{"issue":"8","key":"15_CR49","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","volume":"42","author":"M Debiec-Rychter","year":"2006","unstructured":"Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42(8):1093\u20131103","journal-title":"Eur J Cancer"},{"issue":"23","key":"15_CR50","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol Off J Am Soc Clin Oncol 23(23):5357\u20135364","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5607","key":"15_CR51","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708\u2013710","journal-title":"Science"},{"issue":"4892","key":"15_CR52","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1126\/science.2536956","volume":"243","author":"T Matsui","year":"1989","unstructured":"Matsui T, Heidaran M, Miki T, Popescu N, La Rochelle W, Kraus M et al (1989) Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 243(4892):800\u2013804","journal-title":"Science"},{"issue":"10","key":"15_CR53","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1357-2725(99)00078-3","volume":"31","author":"D Linnekin","year":"1999","unstructured":"Linnekin D (1999) Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 31(10):1053\u20131074","journal-title":"Int J Biochem Cell Biol"},{"key":"15_CR54","doi-asserted-by":"crossref","unstructured":"Mandelker D, Marra A, Mehta N, Selenica P, Yelskaya Z, Yang C et al (2023) Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. NPJ Precis Oncol 7(1):1","DOI":"10.1038\/s41698-022-00342-z"},{"issue":"1","key":"15_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R et al (2022) Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 33(1):20\u201333","journal-title":"Ann Oncol"},{"key":"15_CR56","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) (2023) Gastrointestinal stromal tumors. Version 1.2023\u2014March 13, 2023"},{"issue":"9","key":"15_CR57","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1128\/MCB.23.9.3067-3078.2003","volume":"23","author":"PM Chan","year":"2003","unstructured":"Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R (2003) Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 23(9):3067\u20133078","journal-title":"Mol Cell Biol"},{"issue":"19","key":"15_CR58","doi-asserted-by":"publisher","first-page":"13399","DOI":"10.1074\/jbc.274.19.13399","volume":"274","author":"Y Ma","year":"1999","unstructured":"Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ (1999) Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 274(19):13399\u201313402","journal-title":"J Biol Chem"},{"issue":"9","key":"15_CR59","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s11605-009-0842-6","volume":"13","author":"YY Hou","year":"2009","unstructured":"Hou YY, Grabellus F, Weber F, Zhou Y, Tan YS, Li J et al (2009) Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection. J Gastrointest Surg 13(9):1583\u20131592","journal-title":"J Gastrointest Surg"},{"issue":"11","key":"15_CR60","doi-asserted-by":"publisher","first-page":"e79275","DOI":"10.1371\/journal.pone.0079275","volume":"8","author":"X Zhi","year":"2013","unstructured":"Zhi X, Zhou X, Wang W, Xu Z (2013) Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis. PLoS ONE 8(11):e79275","journal-title":"PLoS ONE"},{"issue":"12","key":"15_CR61","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S0046-8177(03)00407-6","volume":"34","author":"J Lasota","year":"2003","unstructured":"Lasota J, Kopczynski J, Sarlomo-Rikala M, Schneider-Stock R, Stachura T, Kordek R et al (2003) KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 34(12):1306\u20131312","journal-title":"Hum Pathol"},{"issue":"4","key":"15_CR62","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/00000478-200604000-00008","volume":"30","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Makhlouf H, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30(4):477\u2013489","journal-title":"Am J Surg Pathol"},{"key":"15_CR63","doi-asserted-by":"crossref","unstructured":"Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, et al (2000) Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 157(4):1091\u20131095","DOI":"10.1016\/S0002-9440(10)64623-8"},{"issue":"4","key":"15_CR64","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/modpathol.2008.2","volume":"21","author":"J Lasota","year":"2008","unstructured":"Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E et al (2008) Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 21(4):476\u2013484","journal-title":"Mod Pathol"},{"issue":"7","key":"15_CR65","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/labinvest.3700122","volume":"84","author":"J Lasota","year":"2004","unstructured":"Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M (2004) A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 84(7):874\u2013883","journal-title":"Lab Invest"},{"issue":"3","key":"15_CR66","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S1525-1578(10)60510-7","volume":"6","author":"E Wardelmann","year":"2004","unstructured":"Wardelmann E, Hrychyk A, Merkelbach-Bruse S, Pauls K, Goldstein J, Hohenberger P et al (2004) Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diag 6(3):197\u2013204","journal-title":"J Mol Diag"},{"issue":"3","key":"15_CR67","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0016-5085(03)01046-1","volume":"125","author":"S Hirota","year":"2003","unstructured":"Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y et al (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125(3):660\u2013667","journal-title":"Gastroenterology"},{"issue":"1","key":"15_CR68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/labinvest.3700360","volume":"86","author":"J Lasota","year":"2006","unstructured":"Lasota J, Stachura J, Miettinen M (2006) GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 86(1):94\u2013100","journal-title":"Lab Invest"},{"issue":"18","key":"15_CR69","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","volume":"22","author":"CL Corless","year":"2004","unstructured":"Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol Off J Am Soc Clin Oncol 22(18):3813\u20133825","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"15_CR70","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fonc.2013.00117","volume":"3","author":"MG Belinsky","year":"2013","unstructured":"Belinsky MG, Rink L, von Mehren M (2013) Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors. Front Oncol 3:117","journal-title":"Front Oncol"},{"issue":"5","key":"15_CR71","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1365-2559.2012.04300.x","volume":"61","author":"LA Doyle","year":"2012","unstructured":"Doyle LA, Nelson D, Heinrich MC, Corless CL, Hornick JL (2012) Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology 61(5):801\u2013809","journal-title":"Histopathology"},{"issue":"1","key":"15_CR72","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1073\/pnas.1009199108","volume":"108","author":"KA Janeway","year":"2011","unstructured":"Janeway KA, Kim SY, Lodish M, Nose V, Rustin P, Gaal J et al (2011) Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 108(1):314\u2013318","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"15_CR73","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ejhg.2012.205","volume":"21","author":"R Celestino","year":"2013","unstructured":"Celestino R, Lima J, Faustino A, Vinagre J, Maximo V, Gouveia A et al (2013) Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT\/PDGFRA\/BRAF gastrointestinal stromal tumors. Eur J Hum Genet 21(5):503\u2013510","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"15_CR74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/PAS.0b013e3182671178","volume":"37","author":"M Miettinen","year":"2013","unstructured":"Miettinen M, Killian JK, Wang ZF, Lasota J, Lau C, Jones L et al (2013) Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol 37(2):234\u2013240","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"15_CR75","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1097\/PAS.0b013e3182260752","volume":"35","author":"M Miettinen","year":"2011","unstructured":"Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J (2011) Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 35(11):1712\u20131721","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"15_CR76","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/gim.2014.115","volume":"17","author":"MA Pantaleo","year":"2015","unstructured":"Pantaleo MA, Lolli C, Nannini M, Astolfi A, Indio V, Saponara M et al (2015) Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genet Med 17(5):391\u2013395","journal-title":"Genet Med"},{"issue":"1","key":"15_CR77","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/ejhg.2013.80","volume":"22","author":"MA Pantaleo","year":"2014","unstructured":"Pantaleo MA, Astolfi A, Urbini M, Nannini M, Paterini P, Indio V et al (2014) Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT\/PDGFRA wild-type GIST. Eur J Hum Genet 22(1):32\u201339","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"15_CR78","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1737","volume":"5","author":"E Gottlieb","year":"2005","unstructured":"Gottlieb E, Tomlinson IP (2005) Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5(11):857\u2013866","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"15_CR79","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","volume":"10","author":"FH van Nederveen","year":"2009","unstructured":"van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM et al (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10(8):764\u2013771","journal-title":"Lancet Oncol"},{"issue":"6","key":"15_CR80","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1086\/324413","volume":"69","author":"AP Gimenez-Roqueplo","year":"2001","unstructured":"Gimenez-Roqueplo AP, Favier J, Rustin P, Mourad JJ, Plouin PF, Corvol P et al (2001) The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 69(6):1186\u20131197","journal-title":"Am J Hum Genet"},{"issue":"1","key":"15_CR81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD et al (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7(1):77\u201385","journal-title":"Cancer Cell"},{"issue":"3","key":"15_CR82","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10456-004-3149-y","volume":"7","author":"KL Osusky","year":"2004","unstructured":"Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L (2004) The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7(3):225\u2013233","journal-title":"Angiogenesis"},{"issue":"1","key":"15_CR83","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9(1):327\u2013337","journal-title":"Clin Cancer Res"},{"issue":"24","key":"15_CR84","doi-asserted-by":"publisher","first-page":"8387","DOI":"10.1073\/pnas.0803383105","volume":"105","author":"C Tarn","year":"2008","unstructured":"Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D et al (2008) Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 105(24):8387\u20138392","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"15_CR85","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cam4.57","volume":"2","author":"C Beadling","year":"2013","unstructured":"Beadling C, Patterson J, Justusson E, Nelson D, Pantaleo MA, Hornick JL et al (2013) Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. Cancer Med 2(1):21\u201331","journal-title":"Cancer Med"},{"issue":"2","key":"15_CR86","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/gcc.22023","volume":"52","author":"MG Belinsky","year":"2013","unstructured":"Belinsky MG, Rink L, Flieder DB, Jahromi MS, Schiffman JD, Godwin AK et al (2013) Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer 52(2):214\u2013224","journal-title":"Genes Chromosomes Cancer"},{"issue":"19","key":"15_CR87","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2013.54.4932","volume":"32","author":"CJ Langer","year":"2014","unstructured":"Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T et al (2014) Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 32(19):2059\u20132066","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"15_CR88","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/gcc.20589","volume":"47","author":"NP Agaram","year":"2008","unstructured":"Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP et al (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47(10):853\u2013859","journal-title":"Genes Chromosomes Cancer"},{"issue":"6892","key":"15_CR89","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949\u2013954","journal-title":"Nature"},{"issue":"10","key":"15_CR90","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 29(10):1239\u20131246","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"15_CR91","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1136\/jcp.2009.064550","volume":"62","author":"A Agaimy","year":"2009","unstructured":"Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A et al (2009) V600E BRAF mutations are alternative early molecular events in a subset of KIT\/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 62(7):613\u2013616","journal-title":"J Clin Pathol"},{"issue":"1","key":"15_CR92","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1309\/AJCPPCKGA2QGBJ1R","volume":"133","author":"I Hostein","year":"2010","unstructured":"Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF et al (2010) BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 133(1):141\u2013148","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"15_CR93","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1158\/1078-0432.CCR-11-2230","volume":"18","author":"C Miranda","year":"2012","unstructured":"Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A et al (2012) KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18(6):1769\u20131776","journal-title":"Clin Cancer Res"},{"issue":"26","key":"15_CR94","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507\u20132516","journal-title":"N Engl J Med"},{"issue":"2","key":"15_CR95","doi-asserted-by":"publisher","first-page":"310","DOI":"10.18632\/oncotarget.864","volume":"4","author":"GS Falchook","year":"2013","unstructured":"Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC et al (2013) BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 4(2):310\u2013315","journal-title":"Oncotarget"},{"issue":"33","key":"15_CR96","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol Off J Am Soc Clin Oncol 26(33):5352\u20135359","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"15_CR97","doi-asserted-by":"crossref","unstructured":"Van Glabbeke MMOK, Rankin C, Simes J, Crowley J, GIST Meta-analysis Group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients (pts). J clin oncol off j Am Soc Clin Oncol 25(18 suppl):10004","DOI":"10.1200\/jco.2007.25.18_suppl.10004"},{"issue":"9863","key":"15_CR98","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295\u2013302","journal-title":"Lancet"},{"issue":"6","key":"15_CR99","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s10637-012-9795-9","volume":"30","author":"SH Park","year":"2012","unstructured":"Park SH, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS et al (2012) Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 30(6):2377\u20132383","journal-title":"Invest New Drugs"},{"issue":"33","key":"15_CR100","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD et al (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol 26(33):5360\u20135367","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"15_CR101","doi-asserted-by":"crossref","unstructured":"Kindler HL CNP, Wroblewski K, Maki RG, D\u2019Adamo DR, Chow WA, Gandara DR, Antonescu C, Stadler WM, Vokes EE (2011) Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase II Consortium trial. J Clin Oncol Off J Am Soc Clin Oncol 29(Suppl; Abstr):10009","DOI":"10.1200\/jco.2011.29.15_suppl.10009"},{"issue":"15","key":"15_CR102","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1200\/JCO.2013.51.2046","volume":"32","author":"CL Corless","year":"2014","unstructured":"Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW et al (2014) Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol Off J Am Soc Clin Oncol 32(15):1563\u20131570","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"15_CR103","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","volume":"66","author":"MM Schittenhelm","year":"2006","unstructured":"Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al (2006) Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66(1):473\u2013481","journal-title":"Cancer Res"},{"issue":"5","key":"15_CR104","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/CAD.0b013e328352cc50","volume":"23","author":"MA Pantaleo","year":"2012","unstructured":"Pantaleo MA, Nannini M, Saponara M, Gnocchi C, Di Scioscio V, Lolli C et al (2012) Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT\/PDGFRA wild-type metastatic gastrointestinal stromal tumours. Anticancer Drugs 23(5):567\u2013572","journal-title":"Anticancer Drugs"},{"key":"15_CR105","unstructured":"Network. NCC. NCCN Clinical Practice Guidelines in Oncology: Gastrointestinal Stromal Tumors (GIST) Version 1.2015. 2015."},{"issue":"7","key":"15_CR106","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472\u2013480","journal-title":"N Engl J Med"},{"key":"15_CR107","doi-asserted-by":"crossref","unstructured":"Gastrointestinal Stromal Tumor Meta-Analysis G (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol Off J Am Soc Clin Oncol 28(7):1247\u20131253","DOI":"10.1200\/JCO.2009.24.2099"},{"issue":"10","key":"15_CR108","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","volume":"11","author":"A Le Cesne","year":"2010","unstructured":"Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F et al (2010) Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11(10):942\u2013949","journal-title":"Lancet Oncol"},{"issue":"5","key":"15_CR109","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ejca.2003.11.025","volume":"40","author":"M Debiec-Rychter","year":"2004","unstructured":"Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M et al (2004) Use of c-KIT\/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40(5):689\u2013695","journal-title":"Eur J Cancer"},{"issue":"29","key":"15_CR110","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","volume":"24","author":"MC Heinrich","year":"2006","unstructured":"Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol Off J Am Soc Clin Oncol. 24(29):4764\u20134774","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"16","key":"15_CR111","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","volume":"18","author":"PA Cassier","year":"2012","unstructured":"Cassier PA, Fumagalli E, Rutkowski P, Schoffski P, Van Glabbeke M, Debiec-Rychter M et al (2012) Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 18(16):4458\u20134464","journal-title":"Clin Cancer Res"},{"issue":"18","key":"15_CR112","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-08-0533","volume":"14","author":"B Dewaele","year":"2008","unstructured":"Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P et al (2008) Activity of dasatinib, a dual SRC\/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 14(18):5749\u20135758","journal-title":"Clin Cancer Res"},{"issue":"4","key":"15_CR113","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol Off J Am Soc Clin Oncol 26(4):620\u2013625","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"15_CR114","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","volume":"11","author":"CR Antonescu","year":"2005","unstructured":"Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11(11):4182\u20134190","journal-title":"Clin Cancer Res"},{"issue":"2","key":"15_CR115","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/j.gastro.2004.11.020","volume":"128","author":"M Debiec-Rychter","year":"2005","unstructured":"Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N et al (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128(2):270\u2013279","journal-title":"Gastroenterology"},{"issue":"12","key":"15_CR116","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","volume":"41","author":"JR Zalcberg","year":"2005","unstructured":"Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41(12):1751\u20131757","journal-title":"Eur J Cancer"},{"issue":"9544","key":"15_CR117","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329\u20131338","journal-title":"Lancet"},{"issue":"9669","key":"15_CR118","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","volume":"373","author":"RP Dematteo","year":"2009","unstructured":"Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097\u20131104","journal-title":"Lancet"},{"issue":"10","key":"15_CR119","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","volume":"39","author":"H Joensuu","year":"2008","unstructured":"Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39(10):1411\u20131419","journal-title":"Hum Pathol"},{"issue":"12","key":"15_CR120","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12):1265\u20131272","journal-title":"JAMA"},{"issue":"5","key":"15_CR121","first-page":"471","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2(5):471\u2013478","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"15_CR122","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","volume":"20","author":"LJ Murray","year":"2003","unstructured":"Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W et al (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20(8):757\u2013766","journal-title":"Clin Exp Metastasis"},{"issue":"22","key":"15_CR123","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1158\/1078-0432.CCR-09-1315","volume":"15","author":"T Guo","year":"2009","unstructured":"Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD et al (2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 15(22):6862\u20136870","journal-title":"Clin Cancer Res"},{"key":"15_CR124","unstructured":"Administration USFD (2018) FDA approves larotrectinib for solid tumors with NTRK gene fusions. https:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions"},{"issue":"8","key":"15_CR125","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378(8):731\u2013739","journal-title":"N Engl J Med"},{"issue":"4","key":"15_CR126","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 21(4):531\u2013540","journal-title":"Lancet Oncol"},{"key":"15_CR127","unstructured":"Administration USFaD (2019) FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc"},{"issue":"2","key":"15_CR128","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol 21(2):271\u2013282","journal-title":"Lancet Oncol"},{"key":"15_CR129","unstructured":"Administration USFaD (2020) FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation"},{"key":"15_CR130","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","volume":"145","author":"RL Jones","year":"2021","unstructured":"Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK et al (2021) Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer 145:132\u2013142","journal-title":"Eur J Cancer"},{"issue":"1","key":"15_CR131","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.2217\/fon-2019-0633","volume":"16","author":"J Nemunaitis","year":"2020","unstructured":"Nemunaitis J, Bauer S, Blay JY, Choucair K, Gelderblom H, George S et al (2020) Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncol 16(1):4251\u20134264","journal-title":"Future Oncol"},{"issue":"7","key":"15_CR132","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H et al (2020) Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21(7):923\u2013934","journal-title":"Lancet Oncol"},{"key":"15_CR133","unstructured":"Administration USFaD (2022) FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"issue":"1","key":"15_CR134","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","volume":"231","author":"RP DeMatteo","year":"2000","unstructured":"DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231(1):51\u201358","journal-title":"Ann Surg"},{"issue":"1","key":"15_CR135","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/01.pas.0000213307.05811.f0","volume":"31","author":"A Agaimy","year":"2007","unstructured":"Agaimy A, Wunsch PH, Hofstaedter F, Blaszyk H, Rummele P, Gaumann A et al (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31(1):113\u2013120","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"15_CR136","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nrgastro.2009.43","volume":"6","author":"PS Sepe","year":"2009","unstructured":"Sepe PS, Brugge WR (2009) A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol 6(6):363\u2013371","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"15_CR137","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00423-008-0449-5","volume":"394","author":"A Agaimy","year":"2009","unstructured":"Agaimy A, Wunsch PH (2009) Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg 394(2):375\u2013381","journal-title":"Langenbecks Arch Surg"},{"key":"15_CR138","doi-asserted-by":"crossref","unstructured":"McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD et al (2012) Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg 215(1):53\u201359 (discussion 9\u201360)","DOI":"10.1016\/j.jamcollsurg.2012.05.008"},{"issue":"12","key":"15_CR139","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/bjs.7222","volume":"97","author":"P Hohenberger","year":"2010","unstructured":"Hohenberger P, Ronellenfitsch U, Oladeji O, Pink D, Strobel P, Wardelmann E et al (2010) Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 97(12):1854\u20131859","journal-title":"Br J Surg"},{"issue":"7","key":"15_CR140","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1245\/s10434-007-9377-9","volume":"14","author":"P Rutkowski","year":"2007","unstructured":"Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M, Wozniak A, Limon J et al (2007) Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 14(7):2018\u20132027","journal-title":"Ann Surg Oncol"},{"key":"15_CR141","doi-asserted-by":"crossref","unstructured":"Novitsky YW, Kercher KW, Sing RF, Heniford BT (2006) Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 243(6):738\u2013745 (discussion 45\u201347)","DOI":"10.1097\/01.sla.0000219739.11758.27"},{"key":"15_CR142","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-2407-11-72","volume":"11","author":"A Blesius","year":"2011","unstructured":"Blesius A, Cassier PA, Bertucci F, Fayette J, Ray-Coquard I, Bui B et al (2011) Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 11:72","journal-title":"BMC Cancer"},{"issue":"7","key":"15_CR143","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ejso.2008.11.005","volume":"35","author":"M Fiore","year":"2009","unstructured":"Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S et al (2009) Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 35(7):739\u2013745","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"15_CR144","first-page":"357","volume":"45","author":"G Antoch","year":"2004","unstructured":"Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J et al (2004) Comparison of PET, CT, and dual-modality PET\/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45(3):357\u2013365","journal-title":"J Nucl Med"},{"issue":"7","key":"15_CR145","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/RLU.0b013e31817792a3","volume":"33","author":"A Shinto","year":"2008","unstructured":"Shinto A, Nair N, Dutt A, Baghel NS (2008) Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. Clin Nucl Med 33(7):486\u2013487","journal-title":"Clin Nucl Med"},{"issue":"1","key":"15_CR146","first-page":"17","volume":"45","author":"I Gayed","year":"2004","unstructured":"Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N et al (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45(1):17\u201321","journal-title":"J Nucl Med"},{"issue":"12","key":"15_CR147","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1245\/s10434-006-9047-3","volume":"13","author":"S Bonvalot","year":"2006","unstructured":"Bonvalot S, Eldweny H, Pechoux CL, Vanel D, Terrier P, Cavalcanti A et al (2006) Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 13(12):1596\u20131603","journal-title":"Ann Surg Oncol"},{"key":"15_CR148","doi-asserted-by":"crossref","unstructured":"Van Den Abbeele AD, Badawi RD, Manola J, Morgan JA, Desai J, Kazanovicz A, St. Armand M, Baum C, Demetri GD (2004) Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. J Clin Oncol 22 (No 14S (July 15 Supplement); 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition))","DOI":"10.1200\/jco.2004.22.14_suppl.3012"},{"key":"15_CR149","unstructured":"Prescribing instructions for Sutent (sunitinib) (2015) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021938s13s17s18lbl.pdf"},{"issue":"1","key":"15_CR150","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G et al (2011) Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129(1):245\u2013255","journal-title":"Int J Cancer"},{"key":"15_CR151","unstructured":"Prescribing instructions for Stivarga (regorafenib) (2015) http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Stivarga_PI.pdf"},{"issue":"7","key":"15_CR152","doi-asserted-by":"publisher","first-page":"e67583","DOI":"10.1371\/journal.pone.0067583","volume":"8","author":"AJ King","year":"2013","unstructured":"King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE et al (2013) Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF\/MEK tool combination reduced skin lesions. PLoS ONE 8(7):e67583","journal-title":"PLoS ONE"},{"key":"15_CR153","unstructured":"Administration USFaD (2022) FDA Grants Accelerated Approval for GIST Combination Therapy. https:\/\/www.rarediseaseadvisor.com\/news\/gist-news-briefs\/fda-grants-accelerated-approval-for-gist-combination-therapy\/"},{"issue":"9","key":"15_CR154","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2006.09.0183","volume":"25","author":"JY Blay","year":"2007","unstructured":"Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol Off J Am Soc Clin Oncol 25(9):1107\u20131113","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"15_CR155","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/01.sla.0000236630.93587.59","volume":"245","author":"RP DeMatteo","year":"2007","unstructured":"DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245(3):347\u2013352","journal-title":"Ann Surg"},{"issue":"3","key":"15_CR156","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/01.sla.0000242710.36384.1b","volume":"245","author":"A Gronchi","year":"2007","unstructured":"Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A et al (2007) Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced\/metastatic GIST. Ann Surg 245(3):341\u2013346","journal-title":"Ann Surg"},{"issue":"4","key":"15_CR157","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ejso.2013.12.020","volume":"40","author":"S Bauer","year":"2014","unstructured":"Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA et al (2014) Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib\u2014analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 40(4):412\u2013419","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"15_CR158","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/SLA.0000000000002281","volume":"268","author":"M Fairweather","year":"2018","unstructured":"Fairweather M, Balachandran VP, Li GZ, Bertagnolli MM, Antonescu C, Tap W et al (2018) Cytoreductive surgery for metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors: a 2-institutional analysis. Ann Surg 268(2):296\u2013302","journal-title":"Ann Surg"},{"issue":"5","key":"15_CR159","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1172\/JCI124108","volume":"129","author":"GA Vitiello","year":"2019","unstructured":"Vitiello GA, Bowler TG, Liu M, Medina BD, Zhang JQ, Param NJ et al (2019) Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. J Clin Invest 129(5):1863\u20131877","journal-title":"J Clin Invest"},{"issue":"1","key":"15_CR160","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/1078-0432.CCR-21-0878","volume":"28","author":"AS Singh","year":"2022","unstructured":"Singh AS, Hecht JR, Rosen L, Wainberg ZA, Wang X, Douek M et al (2022) A randomized phase II study of nivolumab monotherapy or nivolumab combined with ipilimumab in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 28(1):84\u201394","journal-title":"Clin Cancer Res"},{"issue":"3","key":"15_CR161","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D'Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN et al (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19(3):416\u2013426","journal-title":"Lancet Oncol"},{"key":"15_CR162","doi-asserted-by":"crossref","unstructured":"Chen JL, Mahoney MR, George S, Antonescu CR, Liebner DA, Van Tine BA et al (2020) A multicenter phase II study of nivolumab +\/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): results of expansion cohorts. J Clin Oncol 38(15_suppl):11511","DOI":"10.1200\/JCO.2020.38.15_suppl.11511"},{"issue":"1","key":"15_CR163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1940-6207.CAPR-10-0345","volume":"4","author":"H Hampel","year":"2011","unstructured":"Hampel H, de la Chapelle A (2011) The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res 4(1):1\u20135","journal-title":"Cancer Prev Res"},{"issue":"26","key":"15_CR164","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1056\/NEJMoa053493","volume":"354","author":"RA Barnetson","year":"2006","unstructured":"Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354(26):2751\u20132763","journal-title":"N Engl J Med"},{"issue":"18","key":"15_CR165","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa043146","volume":"352","author":"H Hampel","year":"2005","unstructured":"Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851\u20131860","journal-title":"N Engl J Med"},{"issue":"8","key":"15_CR166","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/ajg.2014.186","volume":"109","author":"FM Giardiello","year":"2014","unstructured":"Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW et al (2014) Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol 109(8):1159\u20131179","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"15_CR167","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jnci\/djn499","volume":"101","author":"RC Green","year":"2009","unstructured":"Green RC, Parfrey PS, Woods MO, Younghusband HB (2009) Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 101(5):331\u2013340","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"15_CR168","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0016-5085(99)70510-X","volume":"116","author":"HF Vasen","year":"1999","unstructured":"Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453\u20131456","journal-title":"Gastroenterology"},{"issue":"4","key":"15_CR169","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jnci\/djh034","volume":"96","author":"A Umar","year":"2004","unstructured":"Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261\u2013268","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"15_CR170","doi-asserted-by":"publisher","first-page":"5783","DOI":"10.1200\/JCO.2008.17.5950","volume":"26","author":"H Hampel","year":"2008","unstructured":"Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(35):5783\u20135788","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"15_CR171","doi-asserted-by":"crossref","unstructured":"Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW et al (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223\u2013262 (quiz 63)","DOI":"10.1038\/ajg.2014.435"},{"issue":"2","key":"15_CR172","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/B:FAME.0000039861.30651.c8","volume":"3","author":"A McGivern","year":"2004","unstructured":"McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ, Walsh MD et al (2004) Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 3(2):101\u2013107","journal-title":"Fam Cancer"},{"issue":"2","key":"15_CR173","doi-asserted-by":"publisher","first-page":"69","DOI":"10.7326\/0003-4819-155-2-201107190-00002","volume":"155","author":"U Ladabaum","year":"2011","unstructured":"Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR et al (2011) Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 155(2):69\u201379","journal-title":"Ann Intern Med"},{"issue":"1","key":"15_CR174","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/GIM.0b013e31818fa2db","volume":"11","author":"GE Palomaki","year":"2009","unstructured":"Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11(1):42\u201365","journal-title":"Genet Med"},{"issue":"1","key":"15_CR175","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ng.283","volume":"41","author":"MJ Ligtenberg","year":"2009","unstructured":"Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3\u2019 exons of TACSTD1. Nat Genet 41(1):112\u2013117","journal-title":"Nat Genet"},{"key":"15_CR176","doi-asserted-by":"crossref","unstructured":"Ligtenberg MJ, Kuiper RP, Geurts van Kessel A, Hoogerbrugge N (2013) EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam Cancer 12(2):169\u2013174","DOI":"10.1007\/s10689-012-9591-x"},{"issue":"4\u20135","key":"15_CR177","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1155\/2004\/305058","volume":"20","author":"P Peltomaki","year":"2004","unstructured":"Peltomaki P, Vasen H (2004) Mutations associated with HNPCC predisposition\u2014update of ICG-HNPCC\/INSiGHT mutation database. Dis Markers 20(4\u20135):269\u2013276","journal-title":"Dis Markers"},{"key":"15_CR178","doi-asserted-by":"crossref","unstructured":"Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138(6):2073\u20132087 e3","DOI":"10.1053\/j.gastro.2009.12.064"},{"issue":"7","key":"15_CR179","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/ng1834","volume":"38","author":"DJ Weisenberger","year":"2006","unstructured":"Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38(7):787\u2013793","journal-title":"Nat Genet"},{"issue":"15","key":"15_CR180","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","volume":"96","author":"M Toyota","year":"1999","unstructured":"Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96(15):8681\u20138686","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"15_CR181","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/gcc.20678","volume":"48","author":"RC Niessen","year":"2009","unstructured":"Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO et al (2009) Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 48(8):737\u2013744","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"15_CR182","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3322\/canjclin.56.4.213","volume":"56","author":"YM Hendriks","year":"2006","unstructured":"Hendriks YM, de Jong AE, Morreau H, Tops CM, Vasen HF, Wijnen JT et al (2006) Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 56(4):213\u2013225","journal-title":"CA Cancer J Clin"},{"key":"15_CR183","doi-asserted-by":"crossref","unstructured":"Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, et al (2008) Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 74(3):233\u2013242","DOI":"10.1111\/j.1399-0004.2008.01035.x"},{"issue":"2","key":"15_CR184","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1053\/j.gastro.2009.10.051","volume":"138","author":"LG Capelle","year":"2010","unstructured":"Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ et al (2010) Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 138(2):487\u2013492","journal-title":"Gastroenterology"},{"issue":"22","key":"15_CR185","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1001\/jama.2011.743","volume":"305","author":"V Bonadona","year":"2011","unstructured":"Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305(22):2304\u20132310","journal-title":"JAMA"},{"issue":"1","key":"15_CR186","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/hmg\/6.1.105","volume":"6","author":"MG Dunlop","year":"1997","unstructured":"Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6(1):105\u2013110","journal-title":"Hum Mol Genet"},{"issue":"4","key":"15_CR187","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.cgh.2010.10.033","volume":"9","author":"DL Edelstein","year":"2011","unstructured":"Edelstein DL, Axilbund J, Baxter M, Hylind LM, Romans K, Griffin CA et al (2011) Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol 9(4):340\u2013343","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"15_CR188","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1136\/jmedgenet-2012-101511","volume":"50","author":"E Borras","year":"2013","unstructured":"Borras E, Pineda M, Cadinanos J, Del Valle J, Brieger A, Hinrichsen I et al (2013) Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants. J Med Genet 50(8):552\u2013563","journal-title":"J Med Genet"},{"issue":"3","key":"15_CR189","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jnci\/djp473","volume":"102","author":"L Baglietto","year":"2010","unstructured":"Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB et al (2010) Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 102(3):193\u2013201","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"15_CR190","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1002\/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U","volume":"91","author":"TC Smyrk","year":"2001","unstructured":"Smyrk TC, Watson P, Kaul K, Lynch HT (2001) Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91(12):2417\u20132422","journal-title":"Cancer"},{"issue":"12","key":"15_CR191","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/BF02555362","volume":"29","author":"JP Mecklin","year":"1986","unstructured":"Mecklin JP, Sipponen P, Jarvinen HJ (1986) Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 29(12):849\u2013853","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"15_CR192","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1052-5157(18)30292-7","volume":"7","author":"B Hofstad","year":"1997","unstructured":"Hofstad B, Vatn M (1997) Growth rate of colon polyps and cancer. Gastrointest Endosc Clin N Am 7(3):345\u2013363","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"15_CR193","doi-asserted-by":"crossref","unstructured":"Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329(27):1977\u20131981","DOI":"10.1056\/NEJM199312303292701"},{"issue":"7","key":"15_CR194","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S0959-8049(02)00041-2","volume":"38","author":"JR Jass","year":"2002","unstructured":"Jass JR, Walsh MD, Barker M, Simms LA, Young J, Leggett BA (2002) Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 38(7):858\u2013866","journal-title":"Eur J Cancer"},{"issue":"4","key":"15_CR195","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/labinvest.3780262","volume":"81","author":"S Salahshor","year":"2001","unstructured":"Salahshor S, Koelble K, Rubio C, Lindblom A (2001) Microsatellite Instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab Invest 81(4):535\u2013541","journal-title":"Lab Invest"},{"issue":"3","key":"15_CR196","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10689-012-9537-3","volume":"11","author":"K Pylvanainen","year":"2012","unstructured":"Pylvanainen K, Lehtinen T, Kellokumpu I, Jarvinen H, Mecklin JP (2012) Causes of death of mutation carriers in Finnish Lynch syndrome families. Fam Cancer 11(3):467\u2013471","journal-title":"Fam Cancer"},{"issue":"24","key":"15_CR197","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1056\/NEJMoa0801297","volume":"359","author":"J Burn","year":"2008","unstructured":"Burn J, Bishop DT, Mecklin JP, Macrae F, Moslein G, Olschwang S et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359(24):2567\u20132578","journal-title":"N Engl J Med"},{"issue":"9809","key":"15_CR198","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","volume":"378","author":"J Burn","year":"2011","unstructured":"Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081\u20132087","journal-title":"Lancet"},{"issue":"10240","key":"15_CR199","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","volume":"395","author":"J Burn","year":"2020","unstructured":"Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP et al (2020) Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet 395(10240):1855\u20131863","journal-title":"Lancet"},{"issue":"1","key":"15_CR200","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1897-4287-7-14","volume":"7","author":"YH Choi","year":"2009","unstructured":"Choi YH, Cotterchio M, McKeown-Eyssen G, Neerav M, Bapat B, Boyd K et al (2009) Penetrance of colorectal cancer among MLH1\/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract 7(1):14","journal-title":"Hered Cancer Clin Pract"},{"issue":"5","key":"15_CR201","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0016-5085(00)70168-5","volume":"118","author":"HJ Jarvinen","year":"2000","unstructured":"Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829\u2013834","journal-title":"Gastroenterology"},{"issue":"5","key":"15_CR202","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1399-0004.2011.01802.x","volume":"82","author":"S Stuckless","year":"2012","unstructured":"Stuckless S, Green JS, Morgenstern M, Kennedy C, Green RC, Woods MO et al (2012) Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. Clin Genet 82(5):439\u2013445","journal-title":"Clin Genet"},{"issue":"7524","key":"15_CR203","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/bmj.38606.794560.EB","volume":"331","author":"I Dove-Edwin","year":"2005","unstructured":"Dove-Edwin I, Sasieni P, Adams J, Thomas HJ (2005) Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 331(7524):1047","journal-title":"BMJ"},{"issue":"2","key":"15_CR204","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/j.gastro.2008.04.026","volume":"135","author":"L Senter","year":"2008","unstructured":"Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135(2):419\u2013428","journal-title":"Gastroenterology"},{"key":"15_CR205","doi-asserted-by":"crossref","unstructured":"de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, Menko FH, Taal BG, Kleibeuker JH et al (2002) Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 45(12):1588\u20131594","DOI":"10.1007\/s10350-004-7244-3"},{"issue":"7","key":"15_CR206","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1136\/gut.2010.228056","volume":"60","author":"S Parry","year":"2011","unstructured":"Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM et al (2011) Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 60(7):950\u2013957","journal-title":"Gut"},{"issue":"6","key":"15_CR207","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1245\/s10434-012-2858-5","volume":"20","author":"AK Win","year":"2013","unstructured":"Win AK, Parry S, Parry B, Kalady MF, Macrae FA, Ahnen DJ et al (2013) Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 20(6):1829\u20131836","journal-title":"Ann Surg Oncol"},{"key":"15_CR208","doi-asserted-by":"crossref","unstructured":"de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, Cats A, Menko FH, Griffioen G et al (2003) Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 52(12):1752\u20131755","DOI":"10.1136\/gut.52.12.1752"},{"issue":"5","key":"15_CR209","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/gut.2007.136127","volume":"57","author":"HF Vasen","year":"2008","unstructured":"Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57(5):704\u2013713","journal-title":"Gut"},{"issue":"6131","key":"15_CR210","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/328614a0","volume":"328","author":"WF Bodmer","year":"1987","unstructured":"Bodmer WF, Bailey CJ, Bodmer J, Bussey HJ, Ellis A, Gorman P et al (1987) Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328(6131):614\u2013616","journal-title":"Nature"},{"issue":"2","key":"15_CR211","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/humu.1380030206","volume":"3","author":"ML Bisgaard","year":"1994","unstructured":"Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3(2):121\u2013125","journal-title":"Hum Mutat"},{"issue":"5","key":"15_CR212","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/1097-0142(19900901)66:5<909::AID-CNCR2820660516>3.0.CO;2-H","volume":"66","author":"HT Lynch","year":"1990","unstructured":"Lynch HT, Smyrk TC, Lanspa SJ, Lynch PM, Watson P, Strayhorn PC et al (1990) Phenotypic variation in colorectal adenoma\/cancer expression in two families. Hereditary flat adenoma syndrome. Cancer 66(5):909\u2013915","journal-title":"Cancer"},{"key":"15_CR213","doi-asserted-by":"crossref","unstructured":"Lynch HT, Smyrk T, McGinn T, Lanspa S, Cavalieri J, Lynch J et al (1995) Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 76(12):2427\u20132433","DOI":"10.1002\/1097-0142(19951215)76:12<2427::AID-CNCR2820761205>3.0.CO;2-B"},{"issue":"2","key":"15_CR214","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1053\/j.gastro.2004.05.003","volume":"127","author":"RW Burt","year":"2004","unstructured":"Burt RW, Leppert MF, Slattery ML, Samowitz WS, Spirio LN, Kerber RA et al (2004) Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 127(2):444\u2013451","journal-title":"Gastroenterology"},{"issue":"4","key":"15_CR215","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ijc.21905","volume":"119","author":"S Aretz","year":"2006","unstructured":"Aretz S, Uhlhaas S, Goergens H, Siberg K, Vogel M, Pagenstecher C et al (2006) MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer 119(4):807\u2013814","journal-title":"Int J Cancer"},{"issue":"5","key":"15_CR216","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759\u2013767","journal-title":"Cell"},{"issue":"3","key":"15_CR217","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1053\/gast.2000.16507","volume":"119","author":"DC Chung","year":"2000","unstructured":"Chung DC (2000) The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 119(3):854\u2013865","journal-title":"Gastroenterology"},{"issue":"1","key":"15_CR218","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/sj.ejhg.5201088","volume":"12","author":"S Aretz","year":"2004","unstructured":"Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P et al (2004) Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 12(1):52\u201358","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"15_CR219","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0002-9440(10)61155-8","volume":"160","author":"C Groves","year":"2002","unstructured":"Groves C, Lamlum H, Crabtree M, Williamson J, Taylor C, Bass S et al (2002) Mutation cluster region, association between germline and somatic mutations and genotype-phenotype correlation in upper gastrointestinal familial adenomatous polyposis. Am J Pathol 160(6):2055\u20132061","journal-title":"Am J Pathol"},{"issue":"13","key":"15_CR220","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/hmg\/ddn095","volume":"17","author":"EM Kohler","year":"2008","unstructured":"Kohler EM, Derungs A, Daum G, Behrens J, Schneikert J (2008) Functional definition of the mutation cluster region of adenomatous polyposis coli in colorectal tumours. Hum Mol Genet 17(13):1978\u20131987","journal-title":"Hum Mol Genet"},{"issue":"6","key":"15_CR221","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/humu.1380020602","volume":"2","author":"H Nagase","year":"1993","unstructured":"Nagase H, Nakamura Y (1993) Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 2(6):425\u2013434","journal-title":"Hum Mutat"},{"issue":"14","key":"15_CR222","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMoa012015","volume":"346","author":"FM Giardiello","year":"2002","unstructured":"Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD et al (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346(14):1054\u20131059","journal-title":"N Engl J Med"},{"issue":"1","key":"15_CR223","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/sj.bjc.6601505","volume":"90","author":"EM Boon","year":"2004","unstructured":"Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R et al (2004) Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 90(1):224\u2013229","journal-title":"Br J Cancer"},{"issue":"3","key":"15_CR224","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/0016-5085(95)90411-5","volume":"109","author":"PJ Pasricha","year":"1995","unstructured":"Pasricha PJ, Bedi A, O\u2019Connor K, Rashid A, Akhtar AJ, Zahurak ML et al (1995) The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109(3):994\u2013998","journal-title":"Gastroenterology"},{"issue":"5","key":"15_CR225","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0092-8674(00)81988-1","volume":"87","author":"M Oshima","year":"1996","unstructured":"Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803\u2013809","journal-title":"Cell"},{"issue":"26","key":"15_CR226","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","volume":"342","author":"G Steinbach","year":"2000","unstructured":"Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946\u20131952","journal-title":"N Engl J Med"},{"issue":"11","key":"15_CR227","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071\u20131080","journal-title":"N Engl J Med"},{"issue":"16","key":"15_CR228","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","volume":"117","author":"SD Solomon","year":"2008","unstructured":"Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM et al (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117(16):2104\u20132113","journal-title":"Circulation"},{"issue":"9651","key":"15_CR229","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(08)61490-7","volume":"372","author":"JA Baron","year":"2008","unstructured":"Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R et al (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372(9651):1756\u20131764","journal-title":"Lancet"},{"issue":"5","key":"15_CR230","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1940-6207.CAPR-11-0106","volume":"4","author":"J Burn","year":"2011","unstructured":"Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG et al (2011) A randomized placebo-controlled prevention trial of aspirin and\/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res 4(5):655\u2013665","journal-title":"Cancer Prev Res"},{"issue":"12","key":"15_CR231","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1080\/003655200453638","volume":"35","author":"I Heiskanen","year":"2000","unstructured":"Heiskanen I, Luostarinen T, Jarvinen HJ (2000) Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 35(12):1284\u20131287","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"15_CR232","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10689-010-9394-x","volume":"10","author":"DC Gibbons","year":"2011","unstructured":"Gibbons DC, Sinha A, Phillips RK, Clark SK (2011) Colorectal cancer: no longer the issue in familial adenomatous polyposis? Fam Cancer 10(1):11\u201320","journal-title":"Fam Cancer"},{"issue":"10","key":"15_CR233","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1136\/gut.2010.212449","volume":"59","author":"EK Mallinson","year":"2010","unstructured":"Mallinson EK, Newton KF, Bowen J, Lalloo F, Clancy T, Hill J et al (2010) The impact of screening and genetic registration on mortality and colorectal cancer incidence in familial adenomatous polyposis. Gut 59(10):1378\u20131382","journal-title":"Gut"},{"issue":"5","key":"15_CR234","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/gut.2009.179804","volume":"59","author":"SR Cairns","year":"2010","unstructured":"Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD et al (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59(5):666\u2013689","journal-title":"Gut"},{"issue":"4","key":"15_CR235","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1053\/j.gastro.2008.12.050","volume":"136","author":"SP Cleary","year":"2009","unstructured":"Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R et al (2009) Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 136(4):1251\u20131260","journal-title":"Gastroenterology"},{"key":"15_CR236","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1471-2407-9-184","volume":"9","author":"M Nielsen","year":"2009","unstructured":"Nielsen M, de Miranda NF, van Puijenbroek M, Jordanova ES, Middeldorp A, van Wezel T et al (2009) Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. BMC Cancer 9:184","journal-title":"BMC Cancer"},{"issue":"6","key":"15_CR237","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1086\/301883","volume":"62","author":"C Soravia","year":"1998","unstructured":"Soravia C, Berk T, Madlensky L, Mitri A, Cheng H, Gallinger S et al (1998) Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 62(6):1290\u20131301","journal-title":"Am J Hum Genet"},{"key":"15_CR238","doi-asserted-by":"crossref","unstructured":"Hegde M, Ferber M, Mao R, Samowitz W, Ganguly A, Working Group of the American College of Medical G et al (2014) ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med 16(1):101\u2013116","DOI":"10.1038\/gim.2013.166"},{"key":"15_CR239","doi-asserted-by":"crossref","unstructured":"Knudsen AL, Bisgaard ML, Bulow S (2003) Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2(1):43\u201355","DOI":"10.1023\/A:1023286520725"},{"key":"15_CR240","doi-asserted-by":"crossref","unstructured":"Nielsen M, Joerink-van de Beld MC, Jones N, Vogt S, Tops CM, Vasen HF et al (2009) Analysis of MUTYH genotypes and colorectal phenotypes in patients with MUTYH-associated polyposis. Gastroenterology 136(2):471\u2013476","DOI":"10.1053\/j.gastro.2008.10.056"},{"issue":"9","key":"15_CR241","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s10350-004-6710-2","volume":"46","author":"J Church","year":"2003","unstructured":"Church J, Burke C, McGannon E, Pastean O, Clark B (2003) Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 46(9):1175\u20131181","journal-title":"Dis Colon Rectum"},{"key":"15_CR242","doi-asserted-by":"crossref","unstructured":"De Cosse JJ, Bulow S, Neale K, Jarvinen H, Alm T, Hultcrantz R et al (1992) Rectal cancer risk in patients treated for familial adenomatous polyposis. The Leeds Castle Polyposis Group. Br J Surg 79(12):1372\u20131375","DOI":"10.1002\/bjs.1800791245"},{"issue":"12","key":"15_CR243","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/BF02236857","volume":"43","author":"JA Bjork","year":"2000","unstructured":"Bjork JA, Akerbrant HI, Iselius LE, Hultcrantz RW (2000) Risk factors for rectal cancer morbidity and mortality in patients with familial adenomatous polyposis after colectomy and ileorectal anastomosis. Dis Colon Rectum 43(12):1719\u20131725","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"15_CR244","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/DCR.0b013e3181a0d33b","volume":"52","author":"MH Nieuwenhuis","year":"2009","unstructured":"Nieuwenhuis MH, Bulow S, Bjork J, Jarvinen HJ, Bulow C, Bisgaard ML et al (2009) Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery. Dis Colon Rectum 52(7):1259\u20131263","journal-title":"Dis Colon Rectum"},{"issue":"9025","key":"15_CR245","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(96)01340-2","volume":"348","author":"HF Vasen","year":"1996","unstructured":"Vasen HF, van der Luijt RB, Slors JF, Buskens E, de Ruiter P, Baeten CG et al (1996) Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 348(9025):433\u2013435","journal-title":"Lancet"},{"issue":"4","key":"15_CR246","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/gut.48.4.515","volume":"48","author":"W Friedl","year":"2001","unstructured":"Friedl W, Caspari R, Sengteller M, Uhlhaas S, Lamberti C, Jungck M et al (2001) Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 48(4):515\u2013521","journal-title":"Gut"},{"issue":"8","key":"15_CR247","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s10350-007-0240-7","volume":"50","author":"JA Cornish","year":"2007","unstructured":"Cornish JA, Tan E, Teare J, Teoh TG, Rai R, Darzi AW et al (2007) The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 50(8):1128\u20131138","journal-title":"Dis Colon Rectum"},{"issue":"12","key":"15_CR248","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/BF02054529","volume":"39","author":"JM Church","year":"1996","unstructured":"Church JM, Fazio VW, Lavery IC, Oakley JR, Milsom J, McGannon E (1996) Quality of life after prophylactic colectomy and ileorectal anastomosis in patients with familial adenomatous polyposis. Dis Colon Rectum 39(12):1404\u20131408","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"15_CR249","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/bjs.4082","volume":"90","author":"KO Olsen","year":"2003","unstructured":"Olsen KO, Juul S, Bulow S, Jarvinen HJ, Bakka A, Bjork J et al (2003) Female fecundity before and after operation for familial adenomatous polyposis. Br J Surg 90(2):227\u2013231","journal-title":"Br J Surg"},{"key":"15_CR250","doi-asserted-by":"crossref","unstructured":"Soravia C, Klein L, Berk T, O\u2019Connor BI, Cohen Z, McLeod RS (1999) Comparison of ileal pouch-anal anastomosis and ileorectal anastomosis in patients with familial adenomatous polyposis. Dis Colon Rectum 42(8):1028\u20131033 (discussion 33\u201334)","DOI":"10.1007\/BF02236696"},{"issue":"11","key":"15_CR251","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/j.1440-1746.2005.03865.x","volume":"20","author":"E Chow","year":"2005","unstructured":"Chow E, Macrae F (2005) A review of juvenile polyposis syndrome. J Gastroenterol Hepatol 20(11):1634\u20131640","journal-title":"J Gastroenterol Hepatol"},{"key":"15_CR252","first-page":"896","volume":"57","author":"I McColl","year":"1964","unstructured":"McColl I, Busxey HJ, Veale AM, Morson BC (1964) Juvenile polyposis coli. Proc R Soc Med 57:896\u2013897","journal-title":"Proc R Soc Med"},{"issue":"5","key":"15_CR253","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/BF02306370","volume":"2","author":"MC Coburn","year":"1995","unstructured":"Coburn MC, Pricolo VE, DeLuca FG, Bland KI (1995) Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 2(5):386\u2013391","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"15_CR254","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/jmg.35.6.476","volume":"35","author":"DC Desai","year":"1998","unstructured":"Desai DC, Murday V, Phillips RK, Neale KF, Milla P, Hodgson SV (1998) A survey of phenotypic features in juvenile polyposis. J Med Genet 35(6):476\u2013481","journal-title":"J Med Genet"},{"issue":"1","key":"15_CR255","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jmg.3.1.5","volume":"3","author":"AM Veale","year":"1966","unstructured":"Veale AM, McColl I, Bussey HJ, Morson BC (1966) Juvenile polyposis coli. J Med Genet 3(1):5\u201316","journal-title":"J Med Genet"},{"issue":"7\u20138","key":"15_CR256","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/0959-8049(95)00139-A","volume":"31A","author":"FM Giardiello","year":"1995","unstructured":"Giardiello FM, Offerhaus JG (1995) Phenotype and cancer risk of various polyposis syndromes. Eur J Cancer 31A(7\u20138):1085\u20131087","journal-title":"Eur J Cancer"},{"issue":"44","key":"15_CR257","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.3748\/wjg.v17.i44.4839","volume":"17","author":"LA Brosens","year":"2011","unstructured":"Brosens LA, Langeveld D, van Hattem WA, Giardiello FM, Offerhaus GJ (2011) Juvenile polyposis syndrome. World J Gastroenterol 17(44):4839\u20134844","journal-title":"World J Gastroenterol"},{"key":"15_CR258","unstructured":"Hofting I, Pott G, Stolte M (1993) The syndrome of juvenile polyposis. Leber Magen Darm 23(3):107\u2013108, 11\u201312"},{"issue":"8","key":"15_CR259","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/BF02303487","volume":"5","author":"JR Howe","year":"1998","unstructured":"Howe JR, Mitros FA, Summers RW (1998) The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 5(8):751\u2013756","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"15_CR260","first-page":"139","volume":"8","author":"V Murday","year":"1989","unstructured":"Murday V, Slack J (1989) Inherited disorders associated with colorectal cancer. Cancer Surv 8(1):139\u2013157","journal-title":"Cancer Surv"},{"issue":"6","key":"15_CR261","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2559.1988.tb02093.x","volume":"13","author":"JR Jass","year":"1988","unstructured":"Jass JR, Williams CB, Bussey HJ, Morson BC (1988) Juvenile polyposis\u2014a precancerous condition. Histopathology 13(6):619\u2013630","journal-title":"Histopathology"},{"issue":"10","key":"15_CR262","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/DCR.0b013e31826278b3","volume":"55","author":"AR Latchford","year":"2012","unstructured":"Latchford AR, Neale K, Phillips RK, Clark SK (2012) Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome. Dis Colon Rectum 55(10):1038\u20131043","journal-title":"Dis Colon Rectum"},{"issue":"9","key":"15_CR263","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/BF02557528","volume":"9","author":"MG Sayed","year":"2002","unstructured":"Sayed MG, Ahmed AF, Ringold JR, Anderson ME, Bair JL, Mitros FA et al (2002) Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol 9(9):901\u2013906","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"15_CR264","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/jmg.2004.018598","volume":"41","author":"JR Howe","year":"2004","unstructured":"Howe JR, Sayed MG, Ahmed AF, Ringold J, Larsen-Haidle J, Merg A et al (2004) The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet 41(7):484\u2013491","journal-title":"J Med Genet"},{"issue":"19","key":"15_CR265","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1001\/jama.294.19.2465","volume":"294","author":"K Sweet","year":"2005","unstructured":"Sweet K, Willis J, Zhou XP, Gallione C, Sawada T, Alhopuro P et al (2005) Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 294(19):2465\u20132473","journal-title":"JAMA"},{"issue":"1","key":"15_CR266","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1399-0004.2007.00734.x","volume":"71","author":"JR Howe","year":"2007","unstructured":"Howe JR, Haidle JL, Lal G, Bair J, Song C, Pechman B et al (2007) ENG mutations in MADH4\/BMPR1A mutation negative patients with juvenile polyposis. Clin Genet 71(1):91\u201392","journal-title":"Clin Genet"},{"issue":"5","key":"15_CR267","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/gut.2007.142927","volume":"57","author":"WA van Hattem","year":"2008","unstructured":"van Hattem WA, Brosens LA, de Leng WW, Morsink FH, Lens S, Carvalho R et al (2008) Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis. Gut 57(5):623\u2013627","journal-title":"Gut"},{"issue":"1","key":"15_CR268","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1399-0004.2008.01091.x","volume":"75","author":"D Calva-Cerqueira","year":"2009","unstructured":"Calva-Cerqueira D, Chinnathambi S, Pechman B, Bair J, Larsen-Haidle J, Howe JR (2009) The rate of germline mutations and large deletions of SMAD4 and BMPR1A in juvenile polyposis. Clin Genet 75(1):79\u201385","journal-title":"Clin Genet"},{"key":"15_CR269","doi-asserted-by":"crossref","unstructured":"Howe JR, Ringold JC, Summers RW, Mitros FA, Nishimura DY, Stone EM (1998) A gene for familial juvenile polyposis maps to chromosome 18q21.1. Am J Hum Genet 62(5):1129\u20131136","DOI":"10.1086\/301840"},{"issue":"5366","key":"15_CR270","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1126\/science.280.5366.1086","volume":"280","author":"JR Howe","year":"1998","unstructured":"Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sistonen P et al (1998) Mutations in the SMAD4\/DPC4 gene in juvenile polyposis. Science 280(5366):1086\u20131088","journal-title":"Science"},{"issue":"37","key":"15_CR271","doi-asserted-by":"publisher","first-page":"22044","DOI":"10.1074\/jbc.270.37.22044","volume":"270","author":"J Wang","year":"1995","unstructured":"Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J et al (1995) Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270(37):22044\u201322049","journal-title":"J Biol Chem"},{"issue":"7","key":"15_CR272","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0092-8674(00)81296-9","volume":"85","author":"J Massague","year":"1996","unstructured":"Massague J (1996) TGFbeta signaling: receptors, transducers, and Mad proteins. Cell 85(7):947\u2013950","journal-title":"Cell"},{"issue":"4","key":"15_CR273","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0092-8674(00)81250-7","volume":"85","author":"PA Hoodless","year":"1996","unstructured":"Hoodless PA, Haerry T, Abdollah S, Stapleton M, O\u2019Connor MB, Attisano L et al (1996) MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 85(4):489\u2013500","journal-title":"Cell"},{"issue":"4","key":"15_CR274","first-page":"303","volume":"10","author":"LI Gold","year":"1999","unstructured":"Gold LI (1999) The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 10(4):303\u2013360","journal-title":"Crit Rev Oncog"},{"issue":"6583","key":"15_CR275","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/381620a0","volume":"381","author":"F Liu","year":"1996","unstructured":"Liu F, Hata A, Baker JC, Doody J, Carcamo J, Harland RM et al (1996) A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 381(6583):620\u2013623","journal-title":"Nature"},{"issue":"9412","key":"15_CR276","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0140-6736(04)15732-2","volume":"363","author":"CJ Gallione","year":"2004","unstructured":"Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S et al (2004) A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363(9412):852\u2013859","journal-title":"Lancet"},{"issue":"11","key":"15_CR277","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/jmg.2007.052506","volume":"44","author":"S Aretz","year":"2007","unstructured":"Aretz S, Stienen D, Uhlhaas S, Stolte M, Entius MM, Loff S et al (2007) High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. J Med Genet 44(11):702\u2013709","journal-title":"J Med Genet"},{"issue":"1","key":"15_CR278","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/bjs.9693","volume":"102","author":"E Aytac","year":"2015","unstructured":"Aytac E, Sulu B, Heald B, O\u2019Malley M, LaGuardia L, Remzi FH et al (2015) Genotype-defined cancer risk in juvenile polyposis syndrome. Br J Surg 102(1):114\u2013118","journal-title":"Br J Surg"},{"issue":"1","key":"15_CR279","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ et al (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91(1):66\u201367","journal-title":"Am J Med Genet"},{"issue":"2","key":"15_CR280","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/88919","volume":"28","author":"JR Howe","year":"2001","unstructured":"Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM et al (2001) Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28(2):184\u2013187","journal-title":"Nat Genet"},{"issue":"6","key":"15_CR281","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1086\/504301","volume":"78","author":"C Delnatte","year":"2006","unstructured":"Delnatte C, Sanlaville D, Mougenot JF, Vermeesch JR, Houdayer C, Blois MC et al (2006) Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes. Am J Hum Genet 78(6):1066\u20131074","journal-title":"Am J Hum Genet"},{"issue":"2","key":"15_CR282","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1399-0004.2008.01026.x","volume":"74","author":"FH Menko","year":"2008","unstructured":"Menko FH, Kneepkens CM, de Leeuw N, Peeters EA, Van Maldergem L, Kamsteeg EJ et al (2008) Variable phenotypes associated with 10q23 microdeletions involving the PTEN and BMPR1A genes. Clin Genet 74(2):145\u2013154","journal-title":"Clin Genet"},{"issue":"5","key":"15_CR283","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1086\/301847","volume":"62","author":"C Eng","year":"1998","unstructured":"Eng C, Ji H (1998) Molecular classification of the inherited hamartoma polyposis syndromes: clearing the muddied waters. Am J Hum Genet 62(5):1020\u20131022","journal-title":"Am J Hum Genet"},{"key":"15_CR284","doi-asserted-by":"crossref","unstructured":"Dunlop MG, British Society for G, Association of Coloproctology for Great B, Ireland (2002) Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 51(Suppl 5):V21\u2013V27","DOI":"10.1136\/gut.51.suppl_5.v21"},{"key":"15_CR285","doi-asserted-by":"crossref","unstructured":"Oncel M, Church JM, Remzi FH, Fazio VW (2005) Colonic surgery in patients with juvenile polyposis syndrome: a case series. Dis Colon Rectum 48(1):49\u201355 (discussion 6)","DOI":"10.1007\/s10350-004-0749-y"},{"issue":"24","key":"15_CR286","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJM198706113162404","volume":"316","author":"FM Giardiello","year":"1987","unstructured":"Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV et al (1987) Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 316(24):1511\u20131514","journal-title":"N Engl J Med"},{"issue":"1","key":"15_CR287","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/ng0198-38","volume":"18","author":"DE Jenne","year":"1998","unstructured":"Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R et al (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18(1):38\u201343","journal-title":"Nat Genet"},{"issue":"7","key":"15_CR288","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/gut.2009.198499","volume":"59","author":"AD Beggs","year":"2010","unstructured":"Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S et al (2010) Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 59(7):975\u2013986","journal-title":"Gut"},{"key":"15_CR289","doi-asserted-by":"crossref","unstructured":"van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME (2010) High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 105(6):1258\u20131264 (author reply 65)","DOI":"10.1038\/ajg.2009.725"},{"issue":"6","key":"15_CR290","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1053\/gast.2000.20228","volume":"119","author":"FM Giardiello","year":"2000","unstructured":"Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6):1447\u20131453","journal-title":"Gastroenterology"},{"issue":"10","key":"15_CR291","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-06-0083","volume":"12","author":"N Hearle","year":"2006","unstructured":"Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ et al (2006) Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 12(10):3209\u20133215","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15_CR292","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-9896(199905)188:1<1::AID-PATH327>3.0.CO;2-J","volume":"188","author":"FT Bosman","year":"1999","unstructured":"Bosman FT (1999) The hamartoma-adenoma-carcinoma sequence. J Pathol 188(1):1\u20132","journal-title":"J Pathol"},{"issue":"1","key":"15_CR293","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/gut.2005.069062","volume":"55","author":"M Jansen","year":"2006","unstructured":"Jansen M, de Leng WW, Baas AF, Myoshi H, Mathus-Vliegen L, Taketo MM et al (2006) Mucosal prolapse in the pathogenesis of Peutz-Jeghers polyposis. Gut 55(1):1\u20135","journal-title":"Gut"},{"key":"15_CR294","volume-title":"Pathology and genetics of tumours of the digestive system","author":"SRAL Hamilton","year":"2000","unstructured":"Hamilton SRAL (2000) Pathology and genetics of tumours of the digestive system. IARC Press, International Agency for Research on Cancer, Lyon, France"},{"issue":"2","key":"15_CR295","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/sj.bjc.6601030","volume":"89","author":"W Lim","year":"2003","unstructured":"Lim W, Hearle N, Shah B, Murday V, Hodgson SV, Lucassen A et al (2003) Further observations on LKB1\/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 89(2):308\u2013313","journal-title":"Br J Cancer"},{"issue":"5","key":"15_CR296","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1136\/jmg.2005.039875","volume":"43","author":"E Volikos","year":"2006","unstructured":"Volikos E, Robinson J, Aittomaki K, Mecklin JP, Jarvinen H, Westerman AM et al (2006) LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome. J Med Genet 43(5):e18","journal-title":"J Med Genet"},{"issue":"6","key":"15_CR297","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/humu.20253","volume":"26","author":"S Aretz","year":"2005","unstructured":"Aretz S, Stienen D, Uhlhaas S, Loff S, Back W, Pagenstecher C et al (2005) High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat 26(6):513\u2013519","journal-title":"Hum Mutat"},{"issue":"8","key":"15_CR298","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1007\/s10620-006-9435-3","volume":"52","author":"H Mehenni","year":"2007","unstructured":"Mehenni H, Resta N, Guanti G, Mota-Vieira L, Lerner A, Peyman M et al (2007) Molecular and clinical characteristics in 46 families affected with Peutz-Jeghers syndrome. Dig Dis Sci 52(8):1924\u20131933","journal-title":"Dig Dis Sci"},{"issue":"4","key":"15_CR299","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","volume":"7","author":"J Dancey","year":"2010","unstructured":"Dancey J (2010) MTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7(4):209\u2013219","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"15_CR300","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-07-4007","volume":"14","author":"C Wei","year":"2008","unstructured":"Wei C, Amos CI, Zhang N, Wang X, Rashid A, Walker CL et al (2008) Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res 14(4):1167\u20131171","journal-title":"Clin Cancer Res"},{"issue":"19","key":"15_CR301","doi-asserted-by":"publisher","first-page":"12327","DOI":"10.1073\/pnas.192301399","volume":"99","author":"DJ Rossi","year":"2002","unstructured":"Rossi DJ, Ylikorkala A, Korsisaari N, Salovaara R, Luukko K, Launonen V et al (2002) Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. Proc Natl Acad Sci USA 99(19):12327\u201312332","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"15_CR302","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1053\/j.gastro.2004.07.059","volume":"127","author":"L Udd","year":"2004","unstructured":"Udd L, Katajisto P, Rossi DJ, Lepisto A, Lahesmaa AM, Ylikorkala A et al (2004) Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology 127(4):1030\u20131037","journal-title":"Gastroenterology"},{"issue":"12","key":"15_CR303","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1097\/DCR.0b013e318233a11f","volume":"54","author":"AR Latchford","year":"2011","unstructured":"Latchford AR, Neale K, Phillips RK, Clark SK (2011) Peutz-Jeghers syndrome: intriguing suggestion of gastrointestinal cancer prevention from surveillance. Dis Colon Rectum 54(12):1547\u20131551","journal-title":"Dis Colon Rectum"},{"key":"15_CR304","unstructured":"Network NCC (2015) NCCN clinical practice guidelines in oncology: genetic\/familial high-risk assessment: colorectal version I.2015"},{"key":"15_CR305","doi-asserted-by":"crossref","unstructured":"Evaluation of Genomic Applications in P, Prevention Working G (2009) Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11(1):35\u201341","DOI":"10.1097\/GIM.0b013e31818fa2ff"},{"issue":"1","key":"15_CR306","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/156652407779940404","volume":"7","author":"LA Brosens","year":"2007","unstructured":"Brosens LA, van Hattem WA, Jansen M, de Leng WW, Giardiello FM, Offerhaus GJ (2007) Gastrointestinal polyposis syndromes. Curr Mol Med 7(1):29\u201346","journal-title":"Curr Mol Med"},{"issue":"3","key":"15_CR307","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"15_CR308","unstructured":"Cancer Stat Facts: Colorectal Cancer (2023) https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html"},{"issue":"5","key":"15_CR309","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386","journal-title":"Int J Cancer"},{"issue":"5","key":"15_CR310","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/DCR.0000000000000318","volume":"58","author":"PS Tawadros","year":"2015","unstructured":"Tawadros PS, Paquette IM, Hanly AM, Mellgren AF, Rothenberger DA, Madoff RD (2015) Adenocarcinoma of the rectum in patients under age 40 is increasing: impact of signet-ring cell histology. Dis Colon Rectum 58(5):474\u2013478","journal-title":"Dis Colon Rectum"},{"key":"15_CR311","doi-asserted-by":"crossref","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023) Colorectal cancer statistics. CA Cancer J Clin","DOI":"10.3322\/caac.21772"},{"key":"15_CR312","doi-asserted-by":"crossref","unstructured":"Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN (2002) Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137(2):132\u2013141","DOI":"10.7326\/0003-4819-137-2-200207160-00015"},{"issue":"3","key":"15_CR313","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10620-015-3600-5","volume":"60","author":"AG Zauber","year":"2015","unstructured":"Zauber AG (2015) The impact of screening on colorectal cancer mortality and incidence: has it really made a difference? Dig Dis Sci 60(3):681\u2013691","journal-title":"Dig Dis Sci"},{"issue":"4","key":"15_CR314","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/sj.bjc.6602714","volume":"93","author":"W Hamilton","year":"2005","unstructured":"Hamilton W, Round A, Sharp D, Peters TJ (2005) Clinical features of colorectal cancer before diagnosis: a population-based case-control study. Br J Cancer 93(4):399\u2013405","journal-title":"Br J Cancer"},{"issue":"10","key":"15_CR315","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1111\/j.1572-0241.1999.01454.x","volume":"94","author":"SR Majumdar","year":"1999","unstructured":"Majumdar SR, Fletcher RH, Evans AT (1999) How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol 94(10):3039\u20133045","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"15_CR316","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D (2021) Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 325(7):669\u2013685","journal-title":"JAMA"},{"issue":"10","key":"15_CR317","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1111\/j.1572-0241.2001.04677.x","volume":"96","author":"LE Johns","year":"2001","unstructured":"Johns LE, Houlston RS (2001) A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 96(10):2992\u20133003","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"15_CR318","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/s-2005-916274","volume":"18","author":"F Amersi","year":"2005","unstructured":"Amersi F, Agustin M, Ko CY (2005) Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg 18(3):133\u2013140","journal-title":"Clin Colon Rectal Surg"},{"issue":"5 Suppl","key":"15_CR319","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/cncr.22007","volume":"107","author":"J Jackson-Thompson","year":"2006","unstructured":"Jackson-Thompson J, Ahmed F, German RR, Lai SM, Friedman C (2006) Descriptive epidemiology of colorectal cancer in the United States, 1998\u20132001. Cancer 107(5 Suppl):1103\u20131111","journal-title":"Cancer"},{"issue":"4","key":"15_CR320","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","volume":"91","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91(4):854\u2013862","journal-title":"Cancer"},{"issue":"6","key":"15_CR321","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s10552-013-0201-5","volume":"24","author":"CM Johnson","year":"2013","unstructured":"Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B et al (2013) Meta-analyses of colorectal cancer risk factors. Cancer Causes Control 24(6):1207\u20131222","journal-title":"Cancer Causes Control"},{"issue":"6","key":"15_CR322","doi-asserted-by":"publisher","first-page":"e20456","DOI":"10.1371\/journal.pone.0020456","volume":"6","author":"DS Chan","year":"2011","unstructured":"Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E et al (2011) Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS ONE 6(6):e20456","journal-title":"PLoS ONE"},{"issue":"1","key":"15_CR323","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/CEJ.0000000000000011","volume":"24","author":"J Cheng","year":"2015","unstructured":"Cheng J, Chen Y, Wang X, Wang J, Yan Z, Gong G et al (2015) Meta-analysis of prospective cohort studies of cigarette smoking and the incidence of colon and rectal cancers. Eur J Cancer Prev 24(1):6\u201315","journal-title":"Eur J Cancer Prev"},{"issue":"11","key":"15_CR324","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/bjs.9229","volume":"100","author":"KM De Bruijn","year":"2013","unstructured":"De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CH (2013) Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 100(11):1421\u20131429","journal-title":"Br J Surg"},{"issue":"20","key":"15_CR325","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1101\/gad.1593107","volume":"21","author":"AK Rustgi","year":"2007","unstructured":"Rustgi AK (2007) The genetics of hereditary colon cancer. Genes Dev 21(20):2525\u20132538","journal-title":"Genes Dev"},{"issue":"10","key":"15_CR326","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.2016.71.0012","volume":"35","author":"MB Yurgelun","year":"2017","unstructured":"Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL et al (2017) Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 35(10):1086\u20131095","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"15_CR327","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1053\/j.gastro.2009.12.065","volume":"138","author":"MS Pino","year":"2010","unstructured":"Pino MS, Chung DC (2010) The chromosomal instability pathway in colon cancer. Gastroenterology 138(6):2059\u20132072","journal-title":"Gastroenterology"},{"issue":"8","key":"15_CR328","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1093\/annonc\/mdt076","volume":"24","author":"CC Simons","year":"2013","unstructured":"Simons CC, Hughes LA, Smits KM, Khalid-de Bakker CA, de Bruine AP, Carvalho B et al (2013) A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann Oncol 24(8):2048\u20132056","journal-title":"Ann Oncol"},{"issue":"20","key":"15_CR329","first-page":"5283","volume":"59","author":"M Miyazaki","year":"1999","unstructured":"Miyazaki M, Furuya T, Shiraki A, Sato T, Oga A, Sasaki K (1999) The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers. Cancer Res 59(20):5283\u20135285","journal-title":"Cancer Res"},{"issue":"6712","key":"15_CR330","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/25292","volume":"396","author":"C Lengauer","year":"1998","unstructured":"Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396(6712):643\u2013649","journal-title":"Nature"},{"issue":"6625","key":"15_CR331","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/386623a0","volume":"386","author":"C Lengauer","year":"1997","unstructured":"Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386(6625):623\u2013627","journal-title":"Nature"},{"issue":"11","key":"15_CR332","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/ajg.2013.292","volume":"108","author":"D Mouradov","year":"2013","unstructured":"Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY et al (2013) Survival in stage II\/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol 108(11):1785\u20131793","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"15_CR333","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/35101065","volume":"1","author":"PV Jallepalli","year":"2001","unstructured":"Jallepalli PV, Lengauer C (2001) Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer 1(2):109\u2013117","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"15_CR334","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1073\/pnas.051625398","volume":"98","author":"S Thiagalingam","year":"2001","unstructured":"Thiagalingam S, Laken S, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B et al (2001) Mechanisms underlying losses of heterozygosity in human colorectal cancers. Proc Natl Acad Sci USA 98(5):2698\u20132702","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"15_CR335","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/gut.2007.135004","volume":"57","author":"A Walther","year":"2008","unstructured":"Walther A, Houlston R, Tomlinson I (2008) Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 57(7):941\u2013950","journal-title":"Gut"},{"issue":"2","key":"15_CR336","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.tig.2007.11.006","volume":"24","author":"JB Geigl","year":"2008","unstructured":"Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR (2008) Defining \u2018chromosomal instability.\u2019 Trends Genet 24(2):64\u201369","journal-title":"Trends Genet"},{"issue":"5","key":"15_CR337","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1593\/neo.09154","volume":"11","author":"Y Baba","year":"2009","unstructured":"Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S et al (2009) Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 11(5):418\u2013425","journal-title":"Neoplasia"},{"key":"15_CR338","doi-asserted-by":"crossref","unstructured":"Lepage CC, Morden CR, Palmer MCL, Nachtigal MW, McManus KJ (2019) Detecting chromosome instability in cancer: approaches to resolve cell-to-cell heterogeneity. Cancers 11(2)","DOI":"10.3390\/cancers11020226"},{"issue":"2","key":"15_CR339","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/gcc.22013","volume":"52","author":"T Sawada","year":"2013","unstructured":"Sawada T, Yamamoto E, Suzuki H, Nojima M, Maruyama R, Shioi Y et al (2013) Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization. Genes Chromosomes Cancer 52(2):140\u2013149","journal-title":"Genes Chromosomes Cancer"},{"key":"15_CR340","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1471-2407-14-121","volume":"14","author":"B Orsetti","year":"2014","unstructured":"Orsetti B, Selves J, Bascoul-Mollevi C, Lasorsa L, Gordien K, Bibeau F et al (2014) Impact of chromosomal instability on colorectal cancer progression and outcome. BMC Cancer 14:121","journal-title":"BMC Cancer"},{"issue":"1","key":"15_CR341","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/sj.onc.1208194","volume":"24","author":"AM Jones","year":"2005","unstructured":"Jones AM, Douglas EJ, Halford SE, Fiegler H, Gorman PA, Roylance RR et al (2005) Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma. Oncogene 24(1):118\u2013129","journal-title":"Oncogene"},{"issue":"11","key":"15_CR342","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1542-3565(05)00618-X","volume":"3","author":"A Rowan","year":"2005","unstructured":"Rowan A, Halford S, Gaasenbeek M, Kemp Z, Sieber O, Volikos E et al (2005) Refining molecular analysis in the pathways of colorectal carcinogenesis. Clin Gastroenterol Hepatol 3(11):1115\u20131123","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"18","key":"15_CR343","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1200\/JCO.2011.38.6490","volume":"30","author":"T Watanabe","year":"2012","unstructured":"Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K et al (2012) Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 30(18):2256\u20132264","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"15_CR344","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/oxfordjournals.annonc.a058883","volume":"5","author":"R Pazdur","year":"1994","unstructured":"Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E et al (1994) Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol 5(5):468\u2013470","journal-title":"Ann Oncol"},{"issue":"5","key":"15_CR345","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3109\/07357909809084650","volume":"16","author":"TB Clark","year":"1998","unstructured":"Clark TB, Kemeny NE, Conti JA, Huang Y, Andre AM, Stockman J (1998) Phase II trial of docetaxel (Taxotere) for untreated advanced colorectal carcinoma. Cancer Invest 16(5):314\u2013318","journal-title":"Cancer Invest"},{"issue":"6","key":"15_CR346","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccr.2007.04.011","volume":"11","author":"C Swanton","year":"2007","unstructured":"Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E et al (2007) Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11(6):498\u2013512","journal-title":"Cancer Cell"},{"issue":"21","key":"15_CR347","doi-asserted-by":"publisher","first-page":"8671","DOI":"10.1073\/pnas.0811835106","volume":"106","author":"C Swanton","year":"2009","unstructured":"Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q et al (2009) Chromosomal instability determines taxane response. Proc Natl Acad Sci USA 106(21):8671\u20138676","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"15_CR348","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4161\/cc.5.8.2682","volume":"5","author":"C Swanton","year":"2006","unstructured":"Swanton C, Tomlinson I, Downward J (2006) Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 5(8):818\u2013823","journal-title":"Cell Cycle"},{"issue":"1","key":"15_CR349","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1535-6108(02)00235-0","volume":"3","author":"S Anand","year":"2003","unstructured":"Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3(1):51\u201362","journal-title":"Cancer Cell"},{"issue":"5","key":"15_CR350","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s10637-013-9990-3","volume":"31","author":"SY Moorcraft","year":"2013","unstructured":"Moorcraft SY, Chau I, Peckitt C, Cunningham D, Rao S, Yim KL et al (2013) Patupilone in patients with pretreated metastatic\/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Invest New Drugs 31(5):1339\u20131344","journal-title":"Invest New Drugs"},{"issue":"5","key":"15_CR351","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1158\/0008-5472.CAN-10-3604","volume":"71","author":"AJ Lee","year":"2011","unstructured":"Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA et al (2011) Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 71(5):1858\u20131870","journal-title":"Cancer Res"},{"issue":"11","key":"15_CR352","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.28656","volume":"120","author":"BI Zaki","year":"2014","unstructured":"Zaki BI, Suriawinata AA, Eastman AR, Garner KM, Bakhoum SF (2014) Chromosomal instability portends superior response of rectal adenocarcinoma to chemoradiation therapy. Cancer 120(11):1733\u20131742","journal-title":"Cancer"},{"issue":"33","key":"15_CR353","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1200\/JCO.2006.08.2644","volume":"24","author":"GY Locker","year":"2006","unstructured":"Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(33):5313\u20135327","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"15_CR354","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc2645","volume":"9","author":"A Walther","year":"2009","unstructured":"Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9(7):489\u2013499","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"15_CR355","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/gut.2005.082933","volume":"55","author":"S Ogino","year":"2006","unstructured":"Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ et al (2006) CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55(7):1000\u20131006","journal-title":"Gut"},{"issue":"3","key":"15_CR356","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1053\/j.gastro.2005.06.020","volume":"129","author":"WS Samowitz","year":"2005","unstructured":"Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA et al (2005) Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129(3):837\u2013845","journal-title":"Gastroenterology"},{"issue":"12","key":"15_CR357","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrc1507","volume":"4","author":"JP Issa","year":"2004","unstructured":"Issa JP (2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4(12):988\u2013993","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"15_CR358","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0002-9440(10)63878-3","volume":"162","author":"SJ Park","year":"2003","unstructured":"Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR, Wu TT (2003) Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol 162(3):815\u2013822","journal-title":"Am J Pathol"},{"issue":"7","key":"15_CR359","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/ijc.33425","volume":"148","author":"BTB Flatin","year":"2021","unstructured":"Flatin BTB, Vedeld HM, Pinto R, Langerud J, Lind GE, Lothe RA et al (2021) Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability. Int J Cancer 148(7):1652\u20131657","journal-title":"Int J Cancer"},{"issue":"3","key":"15_CR360","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2353\/jmoldx.2007.060170","volume":"9","author":"S Ogino","year":"2007","unstructured":"Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS (2007) Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 9(3):305\u2013314","journal-title":"J Mol Diagn"},{"issue":"9","key":"15_CR361","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/01.pas.0000213266.84725.d0","volume":"30","author":"S Ogino","year":"2006","unstructured":"Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW et al (2006) Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 30(9):1175\u20131183","journal-title":"Am J Surg Pathol"},{"issue":"23","key":"15_CR362","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/jnci\/djj468","volume":"98","author":"WS Samowitz","year":"2006","unstructured":"Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE et al (2006) Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 98(23):1731\u20131738","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"15_CR363","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jnci\/djq201","volume":"102","author":"D Limsui","year":"2010","unstructured":"Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW et al (2010) Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 102(14):1012\u20131022","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"15_CR364","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/gut.51.6.797","volume":"51","author":"M van Rijnsoever","year":"2002","unstructured":"van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B (2002) Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51(6):797\u2013802","journal-title":"Gut"},{"issue":"1","key":"15_CR365","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.gastro.2006.09.018","volume":"132","author":"A Goel","year":"2007","unstructured":"Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D et al (2007) The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132(1):127\u2013138","journal-title":"Gastroenterology"},{"issue":"20","key":"15_CR366","doi-asserted-by":"publisher","first-page":"8541","DOI":"10.1158\/0008-5472.CAN-08-1171","volume":"68","author":"L Barault","year":"2008","unstructured":"Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P et al (2008) Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 68(20):8541\u20138546","journal-title":"Cancer Res"},{"issue":"2","key":"15_CR367","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1073\/pnas.97.2.710","volume":"97","author":"M Toyota","year":"2000","unstructured":"Toyota M, Ohe-Toyota M, Ahuja N, Issa JP (2000) Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA 97(2):710\u2013715","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"15_CR368","first-page":"2368","volume":"60","author":"M Esteller","year":"2000","unstructured":"Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN et al (2000) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60(9):2368\u20132371","journal-title":"Cancer Res"},{"issue":"5","key":"15_CR369","doi-asserted-by":"publisher","first-page":"582","DOI":"10.2353\/jmoldx.2006.060082","volume":"8","author":"S Ogino","year":"2006","unstructured":"Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS (2006) CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 8(5):582\u2013588","journal-title":"J Mol Diagn"},{"issue":"47","key":"15_CR370","doi-asserted-by":"publisher","first-page":"18654","DOI":"10.1073\/pnas.0704652104","volume":"104","author":"L Shen","year":"2007","unstructured":"Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y et al (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 104(47):18654\u201318659","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"15_CR371","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/gut.2003.037671","volume":"53","author":"T Kambara","year":"2004","unstructured":"Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD et al (2004) BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53(8):1137\u20131144","journal-title":"Gut"},{"issue":"16","key":"15_CR372","first-page":"4878","volume":"63","author":"TL Chan","year":"2003","unstructured":"Chan TL, Zhao W, Leung SY, Yuen ST, Cancer GP (2003) BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 63(16):4878\u20134881","journal-title":"Cancer Res"},{"issue":"11","key":"15_CR373","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1097\/01.pas.0000141404.56839.6a","volume":"28","author":"S Yang","year":"2004","unstructured":"Yang S, Farraye FA, Mack C, Posnik O, O\u2019Brien MJ (2004) BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28(11):1452\u20131459","journal-title":"Am J Surg Pathol"},{"issue":"7051","key":"15_CR374","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nature03890","volume":"436","author":"C Michaloglou","year":"2005","unstructured":"Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436(7051):720\u2013724","journal-title":"Nature"},{"issue":"4","key":"15_CR375","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0002-9440(10)62327-9","volume":"166","author":"R Beach","year":"2005","unstructured":"Beach R, Chan AO, Wu TT, White JA, Morris JS, Lunagomez S et al (2005) BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 166(4):1069\u20131075","journal-title":"Am J Pathol"},{"issue":"5","key":"15_CR376","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","volume":"88","author":"M Serrano","year":"1997","unstructured":"Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88(5):593\u2013602","journal-title":"Cell"},{"issue":"2","key":"15_CR377","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccr.2010.06.013","volume":"18","author":"M Bennecke","year":"2010","unstructured":"Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A et al (2010) Ink4a\/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 18(2):135\u2013146","journal-title":"Cancer Cell"},{"issue":"3","key":"15_CR378","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2007.12.032","volume":"132","author":"N Wajapeyee","year":"2008","unstructured":"Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132(3):363\u2013374","journal-title":"Cell"},{"issue":"11","key":"15_CR379","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/emmm.201000099","volume":"2","author":"LA Carragher","year":"2010","unstructured":"Carragher LA, Snell KR, Giblett SM, Aldridge VS, Patel B, Cook SJ et al (2010) V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med 2(11):458\u2013471","journal-title":"EMBO Mol Med"},{"issue":"3","key":"15_CR380","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/carcin\/bgp179","volume":"31","author":"H Suzuki","year":"2010","unstructured":"Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M et al (2010) IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 31(3):342\u2013349","journal-title":"Carcinogenesis"},{"issue":"6","key":"15_CR381","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1053\/j.gastro.2009.12.066","volume":"138","author":"B Leggett","year":"2010","unstructured":"Leggett B, Whitehall V (2010) Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 138(6):2088\u20132100","journal-title":"Gastroenterology"},{"issue":"3","key":"15_CR382","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1056\/NEJMoa022289","volume":"349","author":"CM Ribic","year":"2003","unstructured":"Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247\u2013257","journal-title":"N Engl J Med"},{"issue":"20","key":"15_CR383","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(20):3219\u20133226","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"22","key":"15_CR384","first-page":"5248","volume":"58","author":"CR Boland","year":"1998","unstructured":"Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248\u20135257","journal-title":"Cancer Res"},{"issue":"3","key":"15_CR385","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.2005.01.086","volume":"23","author":"S Popat","year":"2005","unstructured":"Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol Off J Am Soc Clin Oncol 23(3):609\u2013618","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"15_CR386","first-page":"808","volume":"57","author":"MF Kane","year":"1997","unstructured":"Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H et al (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57(5):808\u2013811","journal-title":"Cancer Res"},{"issue":"3","key":"15_CR387","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/his.14710","volume":"81","author":"M Swets","year":"2022","unstructured":"Swets M, Graham Martinez C, van Vliet S, van Tilburg A, Gelderblom H, Marijnen CAM et al (2022) Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature. Histopathology 81(3):352\u2013362","journal-title":"Histopathology"},{"issue":"23","key":"15_CR388","first-page":"5548","volume":"55","author":"R Parsons","year":"1995","unstructured":"Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW et al (1995) Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55(23):5548\u20135550","journal-title":"Cancer Res"},{"issue":"5215","key":"15_CR389","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1126\/science.7761852","volume":"268","author":"S Markowitz","year":"1995","unstructured":"Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J et al (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268(5215):1336\u20131338","journal-title":"Science"},{"issue":"3","key":"15_CR390","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ng1196-255","volume":"14","author":"RF Souza","year":"1996","unstructured":"Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM et al (1996) Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 14(3):255\u2013257","journal-title":"Nat Genet"},{"issue":"16","key":"15_CR391","first-page":"6046","volume":"61","author":"Y Mori","year":"2001","unstructured":"Mori Y, Yin J, Rashid A, Leggett BA, Young J, Simms L et al (2001) Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability. Cancer Res 61(16):6046\u20136049","journal-title":"Cancer Res"},{"issue":"5302","key":"15_CR392","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.275.5302.967","volume":"275","author":"N Rampino","year":"1997","unstructured":"Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC et al (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275(5302):967\u2013969","journal-title":"Science"},{"issue":"10","key":"15_CR393","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/ijc.21710","volume":"118","author":"B Jung","year":"2006","unstructured":"Jung B, Smith EJ, Doctolero RT, Gervaz P, Alonso JC, Miyai K et al (2006) Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. Int J Cancer 118(10):2509\u20132513","journal-title":"Int J Cancer"},{"issue":"6","key":"15_CR394","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/jcp.52.6.455","volume":"52","author":"JR Jass","year":"1999","unstructured":"Jass JR, Biden KG, Cummings MC, Simms LA, Walsh M, Schoch E et al (1999) Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J Clin Pathol 52(6):455\u2013460","journal-title":"J Clin Pathol"},{"issue":"24","key":"15_CR395","first-page":"5849","volume":"53","author":"RA Lothe","year":"1993","unstructured":"Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L et al (1993) Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53(24):5849\u20135852","journal-title":"Cancer Res"},{"issue":"22","key":"15_CR396","doi-asserted-by":"publisher","first-page":"12122","DOI":"10.1073\/pnas.94.22.12122","volume":"94","author":"S Olschwang","year":"1997","unstructured":"Olschwang S, Hamelin R, Laurent-Puig P, Thuille B, De Rycke Y, Li YJ et al (1997) Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci USA 94(22):12122\u201312127","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"15_CR397","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/(SICI)1098-2264(199911)26:3<247::AID-GCC9>3.0.CO;2-H","volume":"26","author":"S Salahshor","year":"1999","unstructured":"Salahshor S, Kressner U, Pahlman L, Glimelius B, Lindmark G, Lindblom A (1999) Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosomes Cancer 26(3):247\u2013252","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"15_CR398","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1111\/j.1572-0241.2006.00845.x","volume":"101","author":"FA Sinicrope","year":"2006","unstructured":"Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ et al (2006) Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol 101(12):2818\u20132825","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"15_CR399","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.mrfmmm.2004.05.025","volume":"568","author":"CP Raut","year":"2004","unstructured":"Raut CP, Pawlik TM, Rodriguez-Bigas MA (2004) Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res 568(2):275\u2013282","journal-title":"Mutat Res"},{"issue":"2","key":"15_CR400","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/1940-6207.CAPR-11-0288","volume":"5","author":"AN Bartley","year":"2012","unstructured":"Bartley AN, Luthra R, Saraiya DS, Urbauer DL, Broaddus RR (2012) Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res 5(2):320\u2013327","journal-title":"Cancer Prev Res"},{"issue":"8","key":"15_CR401","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/gcc.22070","volume":"52","author":"K Affolter","year":"2013","unstructured":"Affolter K, Samowitz W, Tripp S, Bronner MP (2013) BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer 52(8):748\u2013752","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"15_CR402","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/jnci\/djk033","volume":"99","author":"RM Xicola","year":"2007","unstructured":"Xicola RM, Llor X, Pons E, Castells A, Alenda C, Pinol V et al (2007) Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99(3):244\u2013252","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"15_CR403","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/gast.2002.37070","volume":"123","author":"N Suraweera","year":"2002","unstructured":"Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K et al (2002) Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123(6):1804\u20131811","journal-title":"Gastroenterology"},{"issue":"4\u20135","key":"15_CR404","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1155\/2004\/136734","volume":"20","author":"JW Bacher","year":"2004","unstructured":"Bacher JW, Flanagan LA, Smalley RL, Nassif NA, Burgart LJ, Halberg RB et al (2004) Development of a fluorescent multiplex assay for detection of MSI-high tumors. Dis Markers 20(4\u20135):237\u2013250","journal-title":"Dis Markers"},{"key":"15_CR405","doi-asserted-by":"crossref","unstructured":"Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23(10):2479\u20132516","DOI":"10.1093\/annonc\/mds236"},{"key":"15_CR406","unstructured":"Network NCC (2015) NCCN clinical practice guidelines in oncology: colon cancer version 3.2015"},{"issue":"8","key":"15_CR407","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","volume":"30","author":"C Luchini","year":"2019","unstructured":"Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T et al (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 30(8):1232\u20131243","journal-title":"Ann Oncol"},{"issue":"10","key":"15_CR408","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1200\/JCO.22.02462","volume":"41","author":"P Vikas","year":"2023","unstructured":"Vikas P, Messersmith H, Compton C, Sholl L, Broaddus RR, Davis A et al (2023) Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of college of american pathologists guideline. J Clin Oncol Off J Am Soc Clin Oncol 41(10):1943\u20131948","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"15_CR409","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/gut.42.5.673","volume":"42","author":"JR Jass","year":"1998","unstructured":"Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP et al (1998) Morphology of sporadic colorectal cancer with DNA replication errors. Gut 42(5):673\u2013679","journal-title":"Gut"},{"issue":"1","key":"15_CR410","first-page":"148","volume":"145","author":"H Kim","year":"1994","unstructured":"Kim H, Jen J, Vogelstein B, Hamilton SR (1994) Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145(1):148\u2013156","journal-title":"Am J Pathol"},{"issue":"11","key":"15_CR411","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1158\/1055-9965.EPI-08-0512","volume":"17","author":"JN Poynter","year":"2008","unstructured":"Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, Lindor N et al (2008) Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17(11):3208\u20133215","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"15_CR412","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/bjs.4472","volume":"91","author":"SM Phillips","year":"2004","unstructured":"Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S (2004) Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 91(4):469\u2013475","journal-title":"Br J Surg"},{"issue":"5109","key":"15_CR413","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.8484122","volume":"260","author":"SN Thibodeau","year":"1993","unstructured":"Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260(5109):816\u2013819","journal-title":"Science"},{"issue":"6429","key":"15_CR414","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/363558a0","volume":"363","author":"Y Ionov","year":"1993","unstructured":"Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363(6429):558\u2013561","journal-title":"Nature"},{"issue":"10","key":"15_CR415","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","volume":"29","author":"G Hutchins","year":"2011","unstructured":"Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(10):1261\u20131270","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"15_CR416","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1200\/JCO.2010.33.0092","volume":"29","author":"MM Bertagnolli","year":"2011","unstructured":"Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM et al (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer\u2014a study of CALGB 9581 and 89803. J Clin Oncol Off J Am Soc Clin Oncol 29(23):3153\u20133162","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"15_CR417","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","volume":"28","author":"AD Roth","year":"2010","unstructured":"Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60\u201300 trial. J Clin Oncol Off J Am Soc Clin Oncol 28(3):466\u2013474","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"15","key":"15_CR418","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1016\/j.ejca.2010.05.009","volume":"46","author":"C Guastadisegni","year":"2010","unstructured":"Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E (2010) Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 46(15):2788\u20132798","journal-title":"Eur J Cancer"},{"issue":"2","key":"15_CR419","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","volume":"100","author":"M Koopman","year":"2009","unstructured":"Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF et al (2009) Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100(2):266\u2013273","journal-title":"Br J Cancer"},{"issue":"3","key":"15_CR420","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/0163-7258(90)90056-8","volume":"48","author":"WB Parker","year":"1990","unstructured":"Parker WB, Cheng YC (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48(3):381\u2013395","journal-title":"Pharmacol Ther"},{"issue":"1","key":"15_CR421","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0016-5085(99)70558-5","volume":"117","author":"JM Carethers","year":"1999","unstructured":"Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB et al (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117(1):123\u2013131","journal-title":"Gastroenterology"},{"issue":"1","key":"15_CR422","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ijc.11176","volume":"106","author":"CN Arnold","year":"2003","unstructured":"Arnold CN, Goel A, Boland CR (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106(1):66\u201373","journal-title":"Int J Cancer"},{"issue":"6","key":"15_CR423","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1053\/j.gastro.2004.10.001","volume":"127","author":"A Tajima","year":"2004","unstructured":"Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM (2004) The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 127(6):1678\u20131684","journal-title":"Gastroenterology"},{"issue":"12","key":"15_CR424","doi-asserted-by":"publisher","first-page":"e28117","DOI":"10.1371\/journal.pone.0028117","volume":"6","author":"A Tajima","year":"2011","unstructured":"Tajima A, Iwaizumi M, Tseng-Rogenski S, Cabrera BL, Carethers JM (2011) Both hMutSalpha and hMutSss DNA mismatch repair complexes participate in 5-fluorouracil cytotoxicity. PLoS ONE 6(12):e28117","journal-title":"PLoS ONE"},{"issue":"9217","key":"15_CR425","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(00)02261-3","volume":"355","author":"H Elsaleh","year":"2000","unstructured":"Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355(9217):1745\u20131750","journal-title":"Lancet"},{"issue":"4","key":"15_CR426","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1053\/gast.2000.18161","volume":"119","author":"A Hemminki","year":"2000","unstructured":"Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H (2000) Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119(4):921\u2013928","journal-title":"Gastroenterology"},{"issue":"7","key":"15_CR427","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1200\/JCO.2006.05.8172","volume":"25","author":"GP Kim","year":"2007","unstructured":"Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N et al (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol Off J Am Soc Clin Oncol 25(7):767\u2013772","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"15_CR428","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","volume":"27","author":"D Sargent","year":"2009","unstructured":"Sargent D, Sobrero A, Grothey A, O\u2019Connell MJ, Buyse M, Andre T et al (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol Off J Am Soc Clin Oncol 27(6):872\u2013877","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"15_CR429","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/MEG.0b013e3282e1c5b7","volume":"19","author":"E Alter","year":"2007","unstructured":"Alter E, Phelip JM, Guilhot JN, Matysiak M, Vermorel M, Roblin X (2007) Adjuvant chemotherapy for stage II colon cancer: influence of care structures\u2019 characteristics on a controversial clinical practice. Eur J Gastroenterol Hepatol 19(11):995\u20131001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"26","key":"15_CR430","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509\u20132520","journal-title":"N Engl J Med"},{"issue":"6349","key":"15_CR431","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409\u2013413","journal-title":"Science"},{"issue":"23","key":"15_CR432","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383(23):2207\u20132218","journal-title":"N Engl J Med"},{"issue":"2","key":"15_CR433","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M et al (2022) First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J Clin Oncol Off J Am Soc Clin Oncol 40(2):161\u2013170","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"15_CR434","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A et al (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30(1):44\u201356","journal-title":"Ann Oncol"},{"key":"15_CR435","doi-asserted-by":"publisher","first-page":"1032314","DOI":"10.3389\/fimmu.2022.1032314","volume":"13","author":"W Hou","year":"2022","unstructured":"Hou W, Yi C, Zhu H (2022) Predictive biomarkers of colon cancer immunotherapy: present and future. Front Immunol 13:1032314","journal-title":"Front Immunol"},{"issue":"17","key":"15_CR436","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","volume":"27","author":"SJ Casak","year":"2021","unstructured":"Casak SJ, Marcus L, Fashoyin-Aje L, Mushti SL, Cheng J, Shen YL et al (2021) FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res 27(17):4680\u20134684","journal-title":"Clin Cancer Res"},{"issue":"23","key":"15_CR437","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C et al (2020) Pembrolizumab in microsatellite-instability\u2014high advanced colorectal cancer. N Engl J Med 383(23):2207\u20132218","journal-title":"N Engl J Med"},{"key":"15_CR438","unstructured":"Administration USFaD (2017) FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-nivolumab-accelerated-approval-msi-h-or-dmmr-colorectal-cancer"},{"key":"15_CR439","unstructured":"Administration USFaD (2018) FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-ipilimumab-msi-h-or-dmmr-metastatic-colorectal-cancer"},{"key":"15_CR440","unstructured":"Administraiton USFaD (2023) Package Insert. dostarlimab-gxly injection, for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761174s003s004lbl.pdf"},{"issue":"9","key":"15_CR441","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182\u20131191","journal-title":"Lancet Oncol"},{"issue":"10","key":"15_CR442","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","volume":"33","author":"T Andr\u00e9","year":"2022","unstructured":"Andr\u00e9 T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M et al (2022) Nivolumab\u00a0plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142*. Ann Oncol 33(10):1052\u20131060","journal-title":"Ann Oncol"},{"key":"15_CR443","doi-asserted-by":"crossref","unstructured":"Andre T, Berton D, Curigliano G, Ellard S, P\u00e9rez JMT, Arkenau H-T, et al (2021) Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. J Clin Oncol 39(3_suppl):9","DOI":"10.1200\/JCO.2021.39.3_suppl.9"},{"issue":"8","key":"15_CR444","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.22.00046","volume":"41","author":"D Morton","year":"2023","unstructured":"Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B et al (2023) Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol 41(8):1541\u20131552","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"15_CR445","doi-asserted-by":"crossref","unstructured":"Chalabi MVYL, van den Berg J, Sikorska K, Beets G, Lent AV, Grootscholten MC, Aalbers A, Buller N, Marsman H, Hendriks E, Burger PWA, Aukema T, Oosterling S, Beets-Tan R, Schumacher TN, van Leerdam M, Voest EE, Haanen JBAG (2022) Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Ann Oncol 33","DOI":"10.1016\/j.annonc.2022.08.016"},{"issue":"4","key":"15_CR446","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K et al (2020) Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26(4):566\u2013576","journal-title":"Nat Med"},{"key":"15_CR447","unstructured":"Network NCC (2023) Practice guidlines in oncology: colon cancer. Version 2.2023. Colon Cancer"},{"issue":"2","key":"15_CR448","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127\u2013137","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"15_CR449","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000030116","volume":"21","author":"I Porebska","year":"2000","unstructured":"Porebska I, Harlozinska A, Bojarowski T (2000) Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 21(2):105\u2013115","journal-title":"Tumour Biol"},{"issue":"1","key":"15_CR450","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/annonc\/mdi006","volume":"16","author":"JP Spano","year":"2005","unstructured":"Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R et al (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16(1):102\u2013108","journal-title":"Ann Oncol"},{"issue":"1","key":"15_CR451","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/sj.bjc.6605473","volume":"102","author":"RL Rego","year":"2010","unstructured":"Rego RL, Foster NR, Smyrk TC, Le M, O\u2019Connell MJ, Sargent DJ et al (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 102(1):165\u2013172","journal-title":"Br J Cancer"},{"issue":"8","key":"15_CR452","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1002\/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2","volume":"71","author":"A Mayer","year":"1993","unstructured":"Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H (1993) The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71(8):2454\u20132460","journal-title":"Cancer"},{"issue":"6","key":"15_CR453","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/cncr.22133","volume":"107","author":"J Marshall","year":"2006","unstructured":"Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107(6):1207\u20131218","journal-title":"Cancer"},{"issue":"4","key":"15_CR454","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337\u2013345","journal-title":"N Engl J Med"},{"issue":"7","key":"15_CR455","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1158\/1078-0432.CCR-09-2017","volume":"16","author":"JR Hecht","year":"2010","unstructured":"Hecht JR, Mitchell E, Neubauer MA, Burris HA 3rd, Swanson P, Lopez T et al (2010) Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 16(7):2205\u20132213","journal-title":"Clin Cancer Res"},{"issue":"9","key":"15_CR456","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","volume":"23","author":"KY Chung","year":"2005","unstructured":"Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol Off J Am Soc Clin Oncol 23(9):1803\u20131810","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"15_CR457","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMe0806778","volume":"359","author":"WA Messersmith","year":"2008","unstructured":"Messersmith WA, Ahnen DJ (2008) Targeting EGFR in colorectal cancer. N Engl J Med 359(17):1834\u20131836","journal-title":"N Engl J Med"},{"issue":"14","key":"15_CR458","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408\u20131417","journal-title":"N Engl J Med"},{"issue":"5","key":"15_CR459","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(5):663\u2013671","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9783","key":"15_CR460","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","volume":"377","author":"TS Maughan","year":"2011","unstructured":"Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH et al (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377(9783):2103\u20132114","journal-title":"Lancet"},{"issue":"8","key":"15_CR461","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Lievre","year":"2006","unstructured":"Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8):3992\u20133995","journal-title":"Cancer Res"},{"issue":"10","key":"15_CR462","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(10):1626\u20131634","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"15_CR463","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa0808268","volume":"360","author":"J Tol","year":"2009","unstructured":"Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6):563\u2013572","journal-title":"N Engl J Med"},{"issue":"15","key":"15_CR464","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","volume":"30","author":"KM Tveit","year":"2012","unstructured":"Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S et al (2012) Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol Off J Am Soc Clin Oncol 30(15):1755\u20131762","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"31","key":"15_CR465","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(31):4706\u20134713","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"15_CR466","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","volume":"27","author":"JR Hecht","year":"2009","unstructured":"Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(5):672\u2013680","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"15_CR467","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-11-2246","volume":"18","author":"S Ogino","year":"2012","unstructured":"Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D et al (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18(3):890\u2013900","journal-title":"Clin Cancer Res"},{"issue":"7","key":"15_CR468","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1200\/JCO.2014.58.9325","volume":"33","author":"CE Atreya","year":"2015","unstructured":"Atreya CE, Corcoran RB, Kopetz S (2015) Expanded RAS: refining the patient population. J Clin Oncol Off J Am Soc Clin Oncol 33(7):682\u2013685","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"15_CR469","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ Sorich","year":"2015","unstructured":"Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26(1):13\u201321","journal-title":"Ann Oncol"},{"issue":"11","key":"15_CR470","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11):1023\u20131034","journal-title":"N Engl J Med"},{"key":"15_CR471","doi-asserted-by":"crossref","unstructured":"De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S et al (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16):1812\u20131820","DOI":"10.1001\/jama.2010.1535"},{"issue":"2","key":"15_CR472","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1200\/JCO.2015.63.9674","volume":"34","author":"CJ Allegra","year":"2016","unstructured":"Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A et al (2016) Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American society of clinical oncology provisional clinical opinion update 2015. J Clin Oncol Off J Am Soc Clin Oncol 34(2):179\u2013185","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"15_CR473","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","volume":"8","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Borgonovo K, Barni S (2013) The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 8(3):173\u2013181","journal-title":"Target Oncol"},{"issue":"8","key":"15_CR474","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10350-007-0228-3","volume":"50","author":"MJ Overman","year":"2007","unstructured":"Overman MJ, Hoff PM (2007) EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum 50(8):1259\u20131270","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"15_CR475","first-page":"15","volume":"4","author":"M El Zouhairi","year":"2011","unstructured":"El Zouhairi M, Charabaty A, Pishvaian MJ (2011) Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res 4(1):15\u201321","journal-title":"Gastrointest Cancer Res"},{"issue":"20","key":"15_CR476","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040\u20132048","journal-title":"N Engl J Med"},{"issue":"15","key":"15_CR477","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol Off J Am Soc Clin Oncol 29(15):2011\u20132019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"15_CR478","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ, O\u2019Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757\u20131765","journal-title":"N Engl J Med"},{"issue":"7","key":"15_CR479","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","volume":"22","author":"C Bokemeyer","year":"2011","unstructured":"Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A et al (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22(7):1535\u20131546","journal-title":"Ann Oncol"},{"issue":"12","key":"15_CR480","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nrd2204","volume":"5","author":"L Saltz","year":"2006","unstructured":"Saltz L, Easley C, Kirkpatrick P (2006) Panitumumab. Nat Rev Drug Discov 5(12):987\u2013988","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"15_CR481","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(13):1658\u20131664","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"15_CR482","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1470-2045(13)70163-3","volume":"14","author":"MT Seymour","year":"2013","unstructured":"Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S et al (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 14(8):749\u2013759","journal-title":"Lancet Oncol"},{"issue":"31","key":"15_CR483","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol Off J Am Soc Clin Oncol 28(31):4697\u20134705","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"35","key":"15_CR484","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","volume":"26","author":"F Di Nicolantonio","year":"2008","unstructured":"Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(35):5705\u20135712","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"15_CR485","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","volume":"48","author":"C Bokemeyer","year":"2012","unstructured":"Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M et al (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48(10):1466\u20131475","journal-title":"Eur J Cancer"},{"issue":"7","key":"15_CR486","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1158\/1078-0432.CCR-12-1913","volume":"19","author":"M Peeters","year":"2013","unstructured":"Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J et al (2013) Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 19(7):1902\u20131912","journal-title":"Clin Cancer Res"},{"issue":"6","key":"15_CR487","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855\u2013867","journal-title":"Cell"},{"issue":"1","key":"15_CR488","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1056\/NEJMc0904160","volume":"361","author":"J Tol","year":"2009","unstructured":"Tol J, Nagtegaal ID, Punt CJ (2009) BRAF mutation in metastatic colorectal cancer. N Engl J Med 361(1):98\u201399","journal-title":"N Engl J Med"},{"issue":"8","key":"15_CR489","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W De Roock","year":"2010","unstructured":"De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11(8):753\u2013762","journal-title":"Lancet Oncol"},{"issue":"1 Pt 1","key":"15_CR490","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1158\/1078-0432.CCR-1118-3","volume":"10","author":"G Deng","year":"2004","unstructured":"Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA et al (2004) BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10(1 Pt 1):191\u2013195","journal-title":"Clin Cancer Res"},{"issue":"5","key":"15_CR491","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00428-013-1470-9","volume":"463","author":"A Thiel","year":"2013","unstructured":"Thiel A, Heinonen M, Kantonen J, Gylling A, Lahtinen L, Korhonen M et al (2013) BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch 463(5):613\u2013621","journal-title":"Virchows Arch"},{"issue":"14","key":"15_CR492","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1158\/0008-5472.CAN-05-0404","volume":"65","author":"WS Samowitz","year":"2005","unstructured":"Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA et al (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65(14):6063\u20136069","journal-title":"Cancer Res"},{"issue":"57","key":"15_CR493","doi-asserted-by":"publisher","first-page":"9192","DOI":"10.1038\/sj.onc.1207061","volume":"22","author":"C Oliveira","year":"2003","unstructured":"Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E et al (2003) BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22(57):9192\u20139196","journal-title":"Oncogene"},{"issue":"24","key":"15_CR494","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1038\/sj.onc.1208569","volume":"24","author":"E Domingo","year":"2005","unstructured":"Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espin E et al (2005) BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 24(24):3995\u20133998","journal-title":"Oncogene"},{"issue":"12","key":"15_CR495","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/annonc\/mdq258","volume":"21","author":"A Farina-Sarasqueta","year":"2010","unstructured":"Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ et al (2010) The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 21(12):2396\u20132402","journal-title":"Ann Oncol"},{"issue":"4","key":"15_CR496","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/jso.23675","volume":"110","author":"CC Lin","year":"2014","unstructured":"Lin CC, Lin JK, Lin TC, Chen WS, Yang SH, Wang HS et al (2014) The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. J Surg Oncol 110(4):451\u2013457","journal-title":"J Surg Oncol"},{"key":"15_CR497","doi-asserted-by":"crossref","unstructured":"Park R, Silva LLd, Lee S, Saeed A (2021) Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability\/mismatch repair deficient metastatic colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 39(15_suppl):3557","DOI":"10.1200\/JCO.2021.39.15_suppl.3557"},{"key":"15_CR498","doi-asserted-by":"crossref","unstructured":"Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA et al (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG\/Alliance N0147. J Natl Cancer Inst 106(7)","DOI":"10.1093\/jnci\/dju106"},{"issue":"12","key":"15_CR499","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1111\/codi.12427","volume":"15","author":"C Clancy","year":"2013","unstructured":"Clancy C, Burke JP, Kalady MF, Coffey JC (2013) BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 15(12):e711\u2013e718","journal-title":"Colorectal Dis"},{"issue":"20","key":"15_CR500","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH et al (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20):4623\u20134632","journal-title":"Cancer"},{"issue":"20","key":"15_CR501","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","volume":"20","author":"S Venderbosch","year":"2014","unstructured":"Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D et al (2014) Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 20(20):5322\u20135330","journal-title":"Clin Cancer Res"},{"issue":"10","key":"15_CR502","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1158\/1055-9965.EPI-12-0674","volume":"21","author":"AI Phipps","year":"2012","unstructured":"Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN et al (2012) BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 21(10):1792\u20131798","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"15_CR503","doi-asserted-by":"crossref","unstructured":"Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG\/AGITG CO.17. Clin Cancer Res. 2014;20(3):744\u201353.","DOI":"10.1158\/1078-0432.CCR-13-0606"},{"issue":"7","key":"15_CR504","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/annonc\/mdq318","volume":"21","author":"D Santini","year":"2010","unstructured":"Santini D, Spoto C, Loupakis F, Vincenzi B, Silvestris N, Cremolini C et al (2010) High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol 21(7):1565","journal-title":"Ann Oncol"},{"issue":"5","key":"15_CR505","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1245\/s10434-009-0864-z","volume":"17","author":"A Italiano","year":"2010","unstructured":"Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S et al (2010) KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17(5):1429\u20131434","journal-title":"Ann Surg Oncol"},{"key":"15_CR506","unstructured":"Administration USFaD (2020) FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation"},{"issue":"5","key":"15_CR507","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19(5):603\u2013615","journal-title":"Lancet Oncol"},{"issue":"17","key":"15_CR508","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.18.02459","volume":"37","author":"E Van Cutsem","year":"2019","unstructured":"Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E et al (2019) Binimetinib, encorafenib, and cetuximab triplet therapy for patients with braf v600e-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol Off J Am Soc Clin Oncol 37(17):1460\u20131469","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"15_CR509","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer. N Engl J Med 381(17):1632\u20131643","journal-title":"N Engl J Med"},{"key":"15_CR510","first-page":"1","volume":"42","author":"S Ahcene Djaballah","year":"2022","unstructured":"Ahcene Djaballah S, Daniel F, Milani A, Ricagno G, Lonardi S (2022) HER2 in Colorectal cancer: the long and winding road from negative predictive factor to positive actionable target. Am Soc Clin Oncol Educ Book 42:1\u201314","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"15_CR511","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F et al (2016) Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17(6):738\u2013746","journal-title":"Lancet Oncol"},{"issue":"10","key":"15_CR512","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1634\/theoncologist.2018-0785","volume":"24","author":"A Sartore-Bianchi","year":"2019","unstructured":"Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F et al (2019) HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist 24(10):1395\u20131402","journal-title":"Oncologist"},{"issue":"4","key":"15_CR513","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/path.4679","volume":"238","author":"SD Richman","year":"2016","unstructured":"Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G et al (2016) HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 238(4):562\u2013570","journal-title":"J Pathol"},{"issue":"5","key":"15_CR514","doi-asserted-by":"publisher","first-page":"e98528","DOI":"10.1371\/journal.pone.0098528","volume":"9","author":"AN Seo","year":"2014","unstructured":"Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH et al (2014) HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS ONE 9(5):e98528","journal-title":"PLoS ONE"},{"key":"15_CR515","doi-asserted-by":"crossref","unstructured":"Laurent-Puig P, Balogoun R, Cayre A, Le Malicot K, Tabernero J, Mini E et al (2016) ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann Oncol 27:vi151","DOI":"10.1093\/annonc\/mdw370.08"},{"key":"15_CR516","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00226","volume":"3","author":"K Raghav","year":"2019","unstructured":"Raghav K, Loree JM, Morris JS, Overman MJ, Yu R, Meric-Bernstam F et al (2019) Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol 3:1\u201313","journal-title":"JCO Precis Oncol"},{"issue":"14","key":"15_CR517","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1200\/JCO.2011.39.2613","volume":"30","author":"P Cortazar","year":"2012","unstructured":"Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R (2012) US Food and drug administration approval overview in metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 30(14):1705\u20131711","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"15_CR518","unstructured":"Administration USFaD (2010) Supplement BLA approval. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2010\/103792s5250ltr.pdf"},{"key":"15_CR519","unstructured":"Administration USFaD (2023) FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer"},{"issue":"1","key":"15_CR520","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000346837","volume":"8","author":"N Harbeck","year":"2013","unstructured":"Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Muller V, Fehm T et al (2013) HER2 dimerization inhibitor pertuzumab\u2014mode of action and clinical data in breast cancer. Breast Care 8(1):49\u201355","journal-title":"Breast Care"},{"key":"15_CR521","doi-asserted-by":"publisher","first-page":"e2200609","DOI":"10.1200\/PO.22.00609","volume":"7","author":"ER Ahn","year":"2023","unstructured":"Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J et al (2023) Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: results from the TAPUR study. JCO Precis Oncol 7:e2200609","journal-title":"JCO Precis Oncol"},{"key":"15_CR522","doi-asserted-by":"publisher","first-page":"v199","DOI":"10.1093\/annonc\/mdz246.004","volume":"30","author":"Y Nakamura","year":"2019","unstructured":"Nakamura Y, Okamoto W, Kato T, Hasegawa H, Kato K, Iwasa S et al (2019) TRIUMPH: primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study. Ann Oncol 30:v199\u2013v200","journal-title":"Ann Oncol"},{"issue":"5","key":"15_CR523","doi-asserted-by":"publisher","first-page":"e000911","DOI":"10.1136\/esmoopen-2020-000911","volume":"5","author":"A Sartore-Bianchi","year":"2020","unstructured":"Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S et al (2020) Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 5(5):e000911","journal-title":"ESMO Open."},{"issue":"5","key":"15_CR524","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","volume":"24","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Cercek A, Siena S, Andre T, Ng K, Van Cutsem E et al (2023) Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol 24(5):496\u2013508","journal-title":"Lancet Oncol"},{"issue":"7","key":"15_CR525","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA et al (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597\u2013609","journal-title":"N Engl J Med"},{"issue":"1","key":"15_CR526","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","volume":"14","author":"T Yoshino","year":"2023","unstructured":"Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H et al (2023) Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun 14(1):3332","journal-title":"Nat Commun"},{"issue":"Suppl 3","key":"15_CR527","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3):4\u201310","journal-title":"Oncology"},{"issue":"7058","key":"15_CR528","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nature03987","volume":"437","author":"SM Weis","year":"2005","unstructured":"Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437(7058):497\u2013504","journal-title":"Nature"},{"issue":"11","key":"15_CR529","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","volume":"64","author":"RT Tong","year":"2004","unstructured":"Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64(11):3731\u20133736","journal-title":"Cancer Res"},{"issue":"19","key":"15_CR530","first-page":"4727","volume":"53","author":"LF Brown","year":"1993","unstructured":"Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR et al (1993) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53(19):4727\u20134735","journal-title":"Cancer Res"},{"issue":"5 Suppl 10","key":"15_CR531","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2006.08.002","volume":"33","author":"LM Ellis","year":"2006","unstructured":"Ellis LM (2006) Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 33(5 Suppl 10):S1-7","journal-title":"Semin Oncol"},{"issue":"23","key":"15_CR532","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342","journal-title":"N Engl J Med"},{"issue":"12","key":"15_CR533","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O\u2019Dwyer PJ, Mitchell EP, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol Off J Am Soc Clin Oncol 25(12):1539\u20131544","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"15_CR534","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14(1):29\u201337","journal-title":"Lancet Oncol"},{"issue":"1","key":"15_CR535","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","volume":"29","author":"CJ Allegra","year":"2011","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ, Sharif S, Petrelli NJ, Colangelo LH et al (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol Off J Am Soc Clin Oncol 29(1):11\u201316","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"15_CR536","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2012.44.4711","volume":"31","author":"CJ Allegra","year":"2013","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ, Sharif S, Petrelli NJ, Lopa SH et al (2013) Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial. J Clin Oncol Off J Am Soc Clin Oncol 31(3):359\u2013364","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"15_CR537","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","volume":"13","author":"A de Gramont","year":"2012","unstructured":"de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ et al (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13(12):1225\u20131233","journal-title":"Lancet Oncol"},{"issue":"9","key":"15_CR538","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/sj.bjc.6605925","volume":"103","author":"V Goede","year":"2010","unstructured":"Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC et al (2010) Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103(9):1407\u20131414","journal-title":"Br J Cancer"},{"issue":"18","key":"15_CR539","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","volume":"27","author":"CG Willett","year":"2009","unstructured":"Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV et al (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol Off J Am Soc Clin Oncol 27(18):3020\u20133026","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"15_CR540","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/tpj.2011.37","volume":"12","author":"AK Koutras","year":"2012","unstructured":"Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I et al (2012) Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 12(6):468\u2013475","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"15_CR541","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00384-011-1382-6","volume":"27","author":"TF Hansen","year":"2012","unstructured":"Hansen TF, Christensen R, Andersen RF, Garm Spindler KL, Johnsson A, Jakobsen A (2012) The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis 27(6):715\u2013720","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"15_CR542","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1001\/jama.2011.51","volume":"305","author":"V Ranpura","year":"2011","unstructured":"Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5):487\u2013494","journal-title":"JAMA"},{"issue":"11","key":"15_CR543","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40261-013-0125-6","volume":"33","author":"F Dai","year":"2013","unstructured":"Dai F, Shu L, Bian Y, Wang Z, Yang Z, Chu W et al (2013) Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig 33(11):779\u2013788","journal-title":"Clin Drug Investig"},{"issue":"10","key":"15_CR544","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/archsurg.2011.233","volume":"146","author":"G Manes","year":"2011","unstructured":"Manes G, de Bellis M, Fuccio L, Repici A, Masci E, Ardizzone S et al (2011) Endoscopic palliation in patients with incurable malignant colorectal obstruction by means of self-expanding metal stent: analysis of results and predictors of outcomes in a large multicenter series. Arch Surg 146(10):1157\u20131162","journal-title":"Arch Surg"},{"key":"15_CR545","doi-asserted-by":"crossref","unstructured":"van Halsema EE, van Hooft JE, Small AJ, Baron TH, Garcia-Cano J, Cheon JH et al (2014) Perforation in colorectal stenting: a meta-analysis and a search for risk factors. Gastrointest Endosc 79(6):970\u201382 e7 (quiz 83 e2, 83 e5)","DOI":"10.1016\/j.gie.2013.11.038"},{"issue":"16","key":"15_CR546","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232\u20131239","journal-title":"J Natl Cancer Inst"},{"key":"15_CR547","unstructured":"Prescribing information for Avastin (bevacizumab) (2015) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125085s305lbl.pdf"},{"issue":"28","key":"15_CR548","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol Off J Am Soc Clin Oncol 30(28):3499\u20133506","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"15_CR549","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2014.10.019","volume":"51","author":"P Ruff","year":"2015","unstructured":"Ruff P, Ferry DR, Lakomy R, Prausova J, Van Hazel GA, Hoff PM et al (2015) Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer 51(1):18\u201326","journal-title":"Eur J Cancer"},{"issue":"15","key":"15_CR550","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","volume":"21","author":"SJ Casak","year":"2015","unstructured":"Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H et al (2015) FDA approval summary: ramucirumab for gastric cancer. Clin Cancer Res 21(15):3372\u20133376","journal-title":"Clin Cancer Res"},{"key":"15_CR551","unstructured":"ESMO (2015) FDA approves ramucirumab for metastatic colorectal cancer"},{"issue":"5","key":"15_CR552","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499\u2013508","journal-title":"Lancet Oncol"},{"issue":"12","key":"15_CR553","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB et al (2017) Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 28(12):2932\u20132942","journal-title":"Ann Oncol"},{"issue":"10","key":"15_CR554","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1065\u20131075","journal-title":"Lancet Oncol"},{"key":"15_CR555","doi-asserted-by":"crossref","unstructured":"Venook APND, Lenz H, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD (2014) CALGB\/SWOG 80405: phase III trial of irinotecan\/5-FU\/leucovorin (FOLFIRI) or oxaliplatin\/5-FU\/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32(15):LBA3","DOI":"10.1200\/jco.2014.32.15_suppl.lba3"},{"issue":"13","key":"15_CR556","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cam4.4561","volume":"11","author":"H Wang","year":"2022","unstructured":"Wang H, Li ZW, Ou Q, Wu X, Nagasaka M, Shao Y et al (2022) NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med 11(13):2541\u20132549","journal-title":"Cancer Med"},{"issue":"4","key":"15_CR557","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/path.5779","volume":"255","author":"JH Kim","year":"2021","unstructured":"Kim JH, Hong JH, Choi YL, Lee JA, Seo MK, Lee MS et al (2021) NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions. J Pathol 255(4):399\u2013411","journal-title":"J Pathol"},{"key":"15_CR558","doi-asserted-by":"crossref","unstructured":"Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A et al (2017) ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J Natl Cancer Inst 109(12)","DOI":"10.1093\/jnci\/djx089"},{"key":"15_CR559","doi-asserted-by":"crossref","unstructured":"Bing Z, Wang W, Wang D, Ma T (2021) Identification of RET fusion as mechanisms of resistance to EGFR tyrosine-kinase inhibitors. J Clin Oncol 39(15_suppl):e21074-e","DOI":"10.1200\/JCO.2021.39.15_suppl.e21074"},{"issue":"30","key":"15_CR560","doi-asserted-by":"publisher","first-page":"28929","DOI":"10.18632\/oncotarget.4325","volume":"6","author":"AF Le Rolle","year":"2015","unstructured":"Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S et al (2015) Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 6(30):28929\u201328937","journal-title":"Oncotarget"},{"issue":"6","key":"15_CR561","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/annonc\/mdy090","volume":"29","author":"F Pietrantonio","year":"2018","unstructured":"Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G et al (2018) RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol 29(6):1394\u20131401","journal-title":"Ann Oncol"},{"key":"15_CR562","unstructured":"Administration USFD (2022) FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors"},{"issue":"10","key":"15_CR563","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J et al (2022) Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 23(10):1261\u20131273","journal-title":"Lancet Oncol"},{"issue":"9863","key":"15_CR564","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312","journal-title":"Lancet"},{"issue":"11","key":"15_CR565","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/JCO.2008.18.2071","volume":"27","author":"MM Bertagnolli","year":"2009","unstructured":"Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B et al (2009) Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol Off J Am Soc Clin Oncol 27(11):1814\u20131821","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"15_CR566","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdu499","volume":"26","author":"D Klingbiel","year":"2015","unstructured":"Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S (2015) Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol 26(1):126\u2013132","journal-title":"Ann Oncol"},{"issue":"35","key":"15_CR567","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","volume":"33","author":"T Andre","year":"2015","unstructured":"Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to braf mutation and mismatch repair status of the MOSAIC Study. J Clin Oncol Off J Am Soc Clin Oncol 33(35):4176\u20134187","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"15_CR568","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jamaoncol.2016.5469","volume":"3","author":"FA Sinicrope","year":"2017","unstructured":"Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM et al (2017) Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers\u202f: a secondary analysis of 2 randomized clinical trials. JAMA Oncol 3(4):472\u2013480","journal-title":"JAMA Oncol"},{"issue":"3","key":"15_CR569","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jamaoncol.2017.2899","volume":"4","author":"A Zaanan","year":"2018","unstructured":"Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC et al (2018) Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: a pooled analysis from 2 randomized clinical trials. JAMA Oncol 4(3):379\u2013383","journal-title":"JAMA Oncol"},{"issue":"9","key":"15_CR570","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/annonc\/mdz208","volume":"30","author":"J Taieb","year":"2019","unstructured":"Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E et al (2019) Prognosis of microsatellite instability and\/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol 30(9):1466\u20131471","journal-title":"Ann Oncol"},{"issue":"6","key":"15_CR571","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.20.01600","volume":"39","author":"R Cohen","year":"2021","unstructured":"Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T et al (2021) Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. J Clin Oncol Off J Am Soc Clin Oncol 39(6):642\u2013651","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"15_CR572","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 36(8):773\u2013779","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"15_CR573","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/annonc\/mdu149","volume":"25","author":"YY Juo","year":"2014","unstructured":"Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP et al (2014) Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol 25(12):2314\u20132327","journal-title":"Ann Oncol"},{"issue":"5","key":"15_CR574","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1054\/bjoc.2001.1964","volume":"85","author":"HJ Andreyev","year":"2001","unstructured":"Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ et al (2001) Kirsten ras mutations in patients with colorectal cancer: the \u2018RASCAL II\u2019 study. Br J Cancer 85(5):692\u2013696","journal-title":"Br J Cancer"},{"issue":"35","key":"15_CR575","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","volume":"26","author":"FD Nicolantonio","year":"2008","unstructured":"Nicolantonio FD, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35):5705\u20135712","journal-title":"J Clin Oncol"},{"issue":"1","key":"15_CR576","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ijc.27654","volume":"132","author":"S Stintzing","year":"2013","unstructured":"Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP et al (2013) Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 132(1):236\u2013245","journal-title":"Int J Cancer"},{"key":"15_CR577","unstructured":"Prescribing information for Erbitux (cetuximab) (2015) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125084s225lbl.pdf"},{"key":"15_CR578","unstructured":"Administration USFaD (2020) FDA approves pembrolizumab for first-line treatment of MSI-H\/dMMR colorectal cancer. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer"},{"key":"15_CR579","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1471-2407-11-247","volume":"11","author":"F Loupakis","year":"2011","unstructured":"Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P et al (2011) Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11:247","journal-title":"BMC Cancer"},{"issue":"17","key":"15_CR580","doi-asserted-by":"publisher","first-page":"5783","DOI":"10.1158\/1078-0432.CCR-11-1115","volume":"17","author":"A Gerger","year":"2011","unstructured":"Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P et al (2011) Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 17(17):5783\u20135792","journal-title":"Clin Cancer Res"},{"key":"15_CR581","unstructured":"Prescribing instructions for Zaltrap (ziv-aflibercept) (2015) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125418s000lbl.pdf"},{"key":"15_CR582","doi-asserted-by":"crossref","unstructured":"Drilon A, Subbiah V, Gautschi O, Tomasini P, Braud Fd, Solomon BJ et al (2023) Selpercatinib in patients with RET fusion\u2013positive non\u2013small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial. J Clin Oncol 41(2):385\u2013394","DOI":"10.1200\/JCO.22.00393"},{"issue":"4","key":"15_CR583","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT (2021) Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open 4(4):e214708","journal-title":"JAMA Netw Open"},{"key":"15_CR584","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/ (updated 2023 Apr 19)"},{"issue":"7540","key":"15_CR585","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540):495\u2013501","journal-title":"Nature"},{"issue":"4","key":"15_CR586","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson EA, Bailey P, Chang DK, Biankin AV (2019) Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 16(4):207\u2013220","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"15_CR587","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1038\/ncomms7744","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"Witkiewicz AK, Mcmillan EA, Balaji U, Baek G, Lin W-C, Mansour J et al (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6(1):6744","journal-title":"Nat Commun"},{"key":"15_CR588","doi-asserted-by":"crossref","unstructured":"Jones SN, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801\u20131806","DOI":"10.1126\/science.1164368"},{"issue":"2","key":"15_CR589","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"BJ Raphael","year":"2017","unstructured":"Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C et al (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32(2):185-203.e13","journal-title":"Cancer Cell"},{"issue":"6","key":"15_CR590","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/PPO.0b013e31827459b6","volume":"18","author":"LD Wood","year":"2012","unstructured":"Wood LD, Hruban RH (2012) Pathology and molecular genetics of pancreatic neoplasms. Cancer J 18(6):492\u2013501","journal-title":"Cancer J"},{"key":"15_CR591","doi-asserted-by":"crossref","unstructured":"Ying H, Kimmelman C, Alec, Lyssiotis A, Costas, Hua S, Chu C, Gerald, Fletcher-Sananikone E et al (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656\u2013670","DOI":"10.1016\/j.cell.2012.01.058"},{"issue":"3","key":"15_CR592","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P (2020) Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Natl Rev Gastroenterol Hepatol 17(3):153\u2013168","journal-title":"Natl Rev Gastroenterol Hepatol"},{"issue":"1","key":"15_CR593","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/cancers3010994","volume":"3","author":"T Ozaki","year":"2011","unstructured":"Ozaki T, Nakagawara A (2011) Role of p53 in cell death and human cancers. Cancers 3(1):994\u20131013","journal-title":"Cancers"},{"issue":"20","key":"15_CR594","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","volume":"24","author":"MJ Pishvaian","year":"2018","unstructured":"Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S et al (2018) Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative. Clin Cancer Res 24(20):5018\u20135027","journal-title":"Clin Cancer Res"},{"issue":"11","key":"15_CR595","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","volume":"42","author":"H-F Hu","year":"2021","unstructured":"Hu H-F, Ye Z, Qin Y, Xu X-W, Yu X-J, Zhuo Q-F et al (2021) Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol Sin 42(11):1725\u20131741","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"15_CR596","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.3390\/ijms21103534","volume":"21","author":"J Dardare","year":"2020","unstructured":"Dardare J, Witz A, Merlin J-L, Gilson P, Harl\u00e9 A (2020) SMAD4 and the TGF\u03b2 pathway in patients with pancreatic ductal adenocarcinoma. Int J Mol Sci 21(10):3534","journal-title":"Int J Mol Sci"},{"issue":"20","key":"15_CR597","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.3390\/cancers13205086","volume":"13","author":"DR Principe","year":"2021","unstructured":"Principe DR, Timbers KE, Atia LG, Koch RM, Rana A (2021) TGF\u03b2 signaling in the pancreatic tumor microenvironment. Cancers 13(20):5086","journal-title":"Cancers"},{"issue":"17","key":"15_CR598","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.3390\/cancers13174259","volume":"13","author":"L Perkhofer","year":"2021","unstructured":"Perkhofer L, Golan T, Cuyle P-J, Matysiak-Budnik T, Van Laethem J-L, Macarulla T et al (2021) Targeting DNA damage repair mechanisms in pancreas cancer. Cancers 13(17):4259","journal-title":"Cancers"},{"key":"15_CR599","doi-asserted-by":"crossref","unstructured":"Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP et al (2016) Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Exp Rev Gastroenterol Hepatol 2016:1\u201313","DOI":"10.1586\/17474124.2016.1153424"},{"issue":"24","key":"15_CR600","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1002\/cncr.29664","volume":"121","author":"EE Salo-Mullen","year":"2015","unstructured":"Salo-Mullen EE, O\u2019Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH et al (2015) Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 121(24):4382\u20134388","journal-title":"Cancer"},{"issue":"2","key":"15_CR601","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","volume":"6","author":"NJ Roberts","year":"2016","unstructured":"Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S et al (2016) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6(2):166\u2013175","journal-title":"Cancer Discov"},{"issue":"4","key":"15_CR602","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A et al (2020) Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 21(4):508\u2013518","journal-title":"Lancet Oncol"},{"key":"15_CR603","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00115","volume":"3","author":"MJ Pishvaian","year":"2019","unstructured":"Pishvaian MJ, Blais EM, Brody JR, Rahib L, Lyons E, De Arbeloa P et al (2019) Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumor program. JCO Precis Oncol 3:1\u201310","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"15_CR604","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381(4):317\u2013327","journal-title":"N Engl J Med"},{"issue":"1","key":"15_CR605","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1038\/ncomms8677","volume":"6","author":"R Russell","year":"2015","unstructured":"Russell R, Perkhofer L, Liebau S, Lin Q, Lechel A, Feld FM et al (2015) Loss of ATM accelerates pancreatic cancer formation and epithelial\u2013mesenchymal transition. Nat Commun 6(1):7677","journal-title":"Nat Commun"},{"issue":"6","key":"15_CR606","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E et al (2018) Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 24(6):1326\u20131336","journal-title":"Clin Cancer Res"},{"key":"15_CR607","doi-asserted-by":"crossref","unstructured":"Bian J, Almhanna K (2021) Pancreatic cancer and immune checkpoint inhibitors\u2014still a long way to go. Transl Gastroenterol Hepatol 6:6","DOI":"10.21037\/tgh.2020.04.03"},{"key":"15_CR608","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/CMAR.S267260","volume":"14","author":"C Kole","year":"2022","unstructured":"Kole C, Charalampakis N, Tsakatikas S, Frountzas M, Apostolou K, Schizas D (2022) Immunotherapy in combination with well-established treatment strategies in pancreatic cancer: current insights. Cancer Manag Res 14:1043\u20131061","journal-title":"Cancer Manag Res"},{"issue":"7424","key":"15_CR609","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin AV, Waddell N, Kassahn KS, Gingras M-C, Muthuswamy LB, Johns AL et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491(7424):399\u2013405","journal-title":"Nature"},{"issue":"3","key":"15_CR610","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1309\/AJCP4D7RXOBHLKGJ","volume":"143","author":"RM Roth","year":"2015","unstructured":"Roth RM, Hampel H, Arnold CA, Yearsley MM, Marsh WL, Frankel WL (2015) A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial. Am J Clin Pathol 143(3):336\u2013343","journal-title":"Am J Clin Pathol"},{"issue":"28","key":"15_CR611","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1200\/JCO.2009.23.7784","volume":"27","author":"HJ Jarvinen","year":"2009","unstructured":"Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol Off J Am Soc Clin Oncol 27(28):4793\u20134797","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"18","key":"15_CR612","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJM199305063281805","volume":"328","author":"FM Giardiello","year":"1993","unstructured":"Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328(18):1313\u20131316","journal-title":"N Engl J Med"},{"key":"15_CR613","unstructured":"Howe JLHaJR. GeneReviews\u00ae (2014) In: Pagon RA (ed) Juvenile polyposis syndrome"}],"container-title":["Cancer Treatment and Research","Gastrointestinal Malignancies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-61238-1_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T06:06:27Z","timestamp":1724997987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-61238-1_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031612374","9783031612381"],"references-count":613,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-61238-1_15","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"type":"print","value":"0927-3042"},{"type":"electronic","value":"2509-8497"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"31 August 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}